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Abstract 
 
The in-vitro everted gut sac model has been used extensively in the laboratory environment to 
investigate the transfer of orally administered drugs across the intestinal wall of rodents. This 
model involves excision of fresh tissue from the small intestine, which is then everted and 
sectioned into individual sacs and incubated under mammalian physiological conditions in 
medium containing the target drug. One of the limitations of this model is the need to access 
tissue immediately following euthanasia, greatly restricting applicability for many species. 
This study investigated the movement of a number of drugs across the intestinal wall in rat 
tissue that had been stored at 4 ºC and then utilised for studies within 60 minutes and after 
being stored at 24 h; as well as possum tissue that had been stored for approximately 24 h. 
Transfer of the target drugs fluconazole, digoxin and chloramphenicol were significantly 
greater in the proximal quarter of the small intestine than the distal three, and so this quarter 
was used for remaining experiments. A number of segments could be gained from the length 
of intestine from this quarter and there was no significant difference shown in transfer 
between any segments. 
The transfer rate of drugs appeared to decrease following the initial 20 minutes of incubation, 
and so this initial 20 minutes was investigated in the remaining experiments with rat tissue. 
Digoxin, a recognised P-glycoprotein substrate, demonstrated the anticipated lower transfer 
across the intestinal wall of the rat compared to fluconazole and chloramphenicol. Whilst the 
addition of 5 µg/mL verapamil increased the initial transfer of digoxin across the gut wall, the 
addition of 25 µg/mL verapamil resulted in significantly lower absorption of all three target 
drugs following 20 minutes incubation. 
The transfer of glucose following tissue storage for 0.5 hours was slightly significantly lower 
than the transfer of glucose observed in tissue stored for 24 h. 
The transfer of glucose across the gut wall using possum tissue was investigated at 30, 60 and 
90 minutes incubation, however access to fresh tissue was problematic, and the possum 
EGSM did not demonstrate the anticipated transfer curve. 
The use of lactate dehydrogenase was examined for use as an indicator of cell toxicity, but 
found to be unreliable. 
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This study concluded that whilst this model may not have future use in wildlife studies that 
are performed ex-situ, sufficient correlations were seen in these experiments to suggest 
further studies to validate the EGSM using stored tissue would be warranted. 
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1. Introduction and Literature Review  
In-vitro models make an important contribution to understanding aspects of human and 
animal physiology. They focus on emulating particular structural and/or physiological aspects 
of the body, without the need for invasive procedures, or causing unnecessary discomfort or 
pain to living subjects. 
The everted gut sac model (EGSM) is an in-vitro model used to mimic the transfer of orally 
administered medicines across the gut wall. It has been used to investigate the specific action 
of some of the many cellular transporter proteins, such as P-glycoprotein (P-gp), on oral 
absorption (Wilson and Wiseman, 1954, Barthe et al., 1998a, Boüer et al., 1999, Varma et al., 
2004). The EGSM is a model to investigate aspects of oral drug absorption, as well as 
assisting in creating strategies to improve overall oral absorption (Boüer et al., 1999). Oral 
absorption is the process of the uptake of substances across, or into tissue, and into the 
circulation (Martin, 2015). However oral absorption should not be confused with oral 
bioavailability which is not only influenced by factors including absorption but also by the 
rate of drug elimination. Medicines that are absorbed well orally, for example, may still be 
eliminated from the body by a number of other factors before they reach the site of action, 
resulting in relatively limited bioavailability. Consequently, the EGSM does not provide 
information on drug oral bioavailability.  
The EGSM has been used for decades in laboratory settings (Wilson and Wiseman, 1954), 
but has not been adapted for use outside of a controlled environment. Maintaining tissue 
viability is the significant limiting factor in what species can be studied using this model, 
reducing its use to conventional laboratory animals that have been sacrificed within minutes 
of their tissue being collected, ‘everted’ and incubated in a tissue tank. In addition, conditions 
for its use have only been validated for use in rats, horses and other rodents (Wilson and 
Wiseman, 1954, Clauss and Hörnicke, 1984, Himukai, 1984, Barthe et al., 1998a). Due to the 
unique physiology of different species, it is anticipated that the established EGSM may 
require alteration to ensure it is optimised for use in the species under study. 
In-vitro models have particular applications when researching aspects of wildlife physiology, 
as gaining in-vivo experimental data from rare, valuable, non-domesticated and / or 
aggressive species can be difficult. Our research group’s recent studies into the 
pharmacological profiles of medicines for koalas (Phascolarctos cinereus), have identified 
extremely limited oral bioavailability when dosed with a number of families of drugs 
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(Griffith et al., 2010, Kimble et al., 2013, Black et al., 2014). The same reduction in 
bioavailability was not observed when the same medicines were administered 
subcutaneously. Similar results were observed in another Eucalyptus spp. foliage eating 
marsupial, the common brushtail possum (Pseudocheirus peregrinus) when dosed with the 
bait marker iophenoxic acid (Eason et al., 1994). Although other causes of poor medicine oral 
bioavailability in the koala have been suggested, such as the presence of fibrous ingesta 
which could entrap the medicine, and the relatively reduced absorptive area of their short 
small intestine (Griffith et al 2010), there is also a question whether there is reduced medicine 
transfer across the intestinal cell wall, as horses (a herbivore with a diet not totally dissimilar 
to the folivore diet of the koala) have a high distribution of cellular efflux transporters along 
the gut mucosa (Tydén et al., 2008). It is possible that the gut wall may be a barrier to oral 
xenobiotic absorption due to the presence of cellular efflux pumps. There are a large number 
of influx and efflux pumps located in the small intestine; however the most well studied is P-
glycoprotein (P-gp). Therefore the EGSM may be a useful functional model to ascertain the 
extent of medicinal gut transfer within a species and to compare the extent of transfer across 
species.    
The EGSM could also be useful, as in the case of many wild species, to provide information 
in order to modify the dosages (i.e. dose rate and frequency of administration) of orally 
administered medicines. As to date, the dosages of many medicines used in exotic species 
have been extrapolated from dosages from conventional veterinary species, which in the case 
of koalas, are almost identical to those used for dogs and cats. The optimisation of the EGSM 
for use outside of a laboratory environment would greatly increase the number of species this 
model could be applied to, and in turn, assist in gaining further knowledge of those factors 
that influence transfer of medicines in each of these species. This knowledge is important in 
creating strategies to improve medicine transfer and increase the efficiency of various 
administration routes which are critical to the treatment of wild species. 
 
1.1 Therapeutic dosages in wild species 
There are many indications when medicines are administered to animals. Wild animals are 
usually exposed to medicines during periods of treatment for injury and disease. This 
includes dietary supplements, anaesthetics prior to surgery and various treatments to 
minimise pain, inflammation and shock (Hemsley et al., 1998). Medicines may be 
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administered orally or via subcutaneous, intramuscular or intravenous injection (Hemsley et 
al., 1998, Blanshard and Bodley, 2008, Govendir et al., 2011). However, currently most 
medicine dosages for wild animals are not based on any species specific pharmacokinetic or 
pharmacodynamic studies but extrapolated from domesticated species, resulting in unknown 
bioavailability when dosing many species. 
Recent studies have demonstrated limited oral absorption and rapid elimination in koalas 
when using these extrapolated dosages in a number of different classes of medicines. 
Fluoroquinolones have been investigated for the treatment of chlamydiosis, an endemic 
disease in some south-eastern Queensland and northern NSW koala populations (Comlaw, 
2012). When two fluoroquinolone antibacterial drugs, enrofloxacin and marbofloxacin, were 
administered orally at the suggested dosage (Blanshard and Bodley, 2008), marbofloxacin 
was not detectable in koala plasma, and only four times the recommended dose of 
enrofloxacin was detectable, albeit at much lower concentrations than expected (Griffith et 
al., 2010). From the low concentrations demonstrated by that study, it is unlikely that the 
recommended doses of either medicine were having the desired therapeutic effects. The 
suggested dosages were the same as those administered to cats and dogs, and had not been 
optimised for use in koalas, demonstrating a difference in xenobiotic bioavailability between 
the species (Griffith et al., 2010).   
Fluconazole (FLC) is an antifungal drug currently administered orally to koalas to treat the 
disease cryptococcosis (Wynne et al., 2012). However a recent study showed oral 
bioavailability of FLC to be low and variable within a studied population, with a much 
shorter elimination half-life than expected (Black et al., 2014). These results suggest that, like 
fluoroquinolones, FLC may also not be reaching therapeutic plasma concentrations sufficient 
to treat the desired disease. 
Negligible oral bioavailability was also observed with meloxicam, a commonly prescribed 
non-steroidal anti-inflammatory drug (NSAID) (Kimble et al., 2013). It has been approved 
for use in humans in the treatment of arthritic conditions (Wojtulewski et al., 1996), as well 
as in dogs, cats and horses for relief of pain and inflammation (Slingsby and Waterman‐
Pearson, 2000, Deneuche et al., 2004, Toutain et al., 2004). In the wild koala population, it is 
the most popular analgesic for injured koalas (de Kauwe et al., 2014), as well as being used in 
captive populations for the treatment of arthritis (Pye et al., 2008, Pye, 2009). Despite being 
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the preferential route of administration in many other species, oral bioavailability of 
meloxicam was found to be extremely low (Kimble et al., 2013).  
Similar results have been observed in other marsupials such as the common brushtail possum, 
whose diet also consists of Eucalyptus spp. foliage, although not exclusively. Eason et al. 
(1994) compared the suitability of iophenoxic acid as a bait marker in the brushtail possum 
and feral cat. Following oral ingestion, peak plasma concentration in the cat was six times 
higher than the peak concentration found in brushtail possum plasma (Eason et al., 1994). 
Rapid elimination was also displayed by brushtail possums, as the plasma elimination half-
life for iophenoxic acid was found to be 107 days in the cat, but less than 24 hours in the 
brushtail possum, making it unsuitable for use as a bait marker (Eason et al., 1994). However 
a recent paper demonstrated therapeutic blood concentrations of enrofloxacin were attained in 
the brushtail possum when dosed orally, but not when the same dose was administered 
subcutaneously (Scheelings et al., 2015). This was contradictory to Griffith et al.’s study 
which documented low oral bioavailability of enrofloxacin in the koala. Scheeling et al.’s 
study did, however, demonstrate rapid elimination of enrofloxacin in the brushtail possum, 
similar to that seen in Griffith et al.’s study. 
The significant differences between oral and subcutaneous bioavailability suggest that the 
intestinal wall itself may be having a variable effect on oral medicine absorption between 
species. However, as discussed by Griffith et al. (2010) there are also a number of other 
factors that may be influencing oral absorption. These include the binding of xenobiotics to 
leaf material or metal cations commonly found in Eucalyptus spp. in the stomach and gut, 
making these drugs unavailable for absorption (Griffith, 2010). Physiological factors, such as 
the rapid intestinal transit time and increased first-pass metabolism in koalas have also been 
identified to be likely to affect oral absorption in the species (Griffith, 2010). However, as 
previously discussed, the role of influx and efflux molecular transporters such as P-gp in 
marsupials has not been investigated. The influence of transporter activity, including that of 
P-gp, is an important step in identifying factors that limit oral absorption in marsupials. 
 
1.2 Marsupial gut physiology 
The unique gut physiology of some arboreal marsupials is reflective of their ability to be able 
to process their restrictive diet. The koala’s diet consists almost exclusively of foliage of the 
Eucalyptus genus (Blanshard and Bodley, 2008). This foliage has low nitrogen 
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concentrations, highly lignified cell wall content and a high concentration of tannins, terpenes 
and oils which are toxic in many other species, making it very low in nutrients, and difficult 
to digest (Osawa and Carrick, 1990, Blanshard and Bodley, 2008).  
They are monogastric hindgut fermenters with a small stomach, relatively short small 
intestine, but a very large caecum (Hume, 1999, Blanshard and Bodley, 2008). Unique gut 
flora and enzymes found throughout the gastrointestinal tract (GIT) of the koala are thought 
to be largely responsible for the successful breakdown and digestion of the eucalypt diet 
(Osawa and Carrick, 1990, Pass et al., 2001).   
Similarly, the common ringtail possum (Trichosurus vulpecula) feeds largely on products of 
Eucalyptus spp. vegetation (Johnson and Hemsley, 2008). The diet of the brushtail possum is 
more varied, although it does contain significant amounts of eucalypt foliage as well as 
flowers and fruits (Johnson and Hemsley, 2008). Both species have the ability to digest and 
gain nutrients from this plant group. The digestive physiologies of both species are very 
similar to that of the koala, with digestion occurring through microbial fermentation in the 
large caecum (Johnson and Hemsley, 2008).  
Molecular transporters are found on the membrane of the small intestine as well as many 
other organs (Thiebaut et al., 1987), and are responsible for the influx and efflux of 
substances into and out of cells. Specifically, the transporter P-gp is one that has been 
identified as being responsible for transporting medicines back into the lumen as they are 
absorbed across the intestinal mucosa (Jonker et al., 1999, Tydén et al., 2008, Linardi et al., 
2013). For this reason, P-gp has been identified as playing a possible role in limiting the 
bioavailability of orally administered medicines. 
As previously discussed, the role of molecular transporters such as P-gp in marsupials has not 
been investigated. However, this unique gut physiology, in addition to evidence in other 
species, justifies further investigation into its role in restricting the oral bioavailability of 
different therapeutics. 
 
1.3 Everted gut sac model    
The EGSM was initially developed to study the transport of glucose and amino acids across 
the wall of the GIT, but has been further developed for the study of transport protein activity. 
It has previously been commonly used in the investigation of molecular transporters 
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including P-gp activity in animal species, as well as providing a rodent model to investigate 
digestion for the purposes of understanding possible mechanisms of digestion (Boüer et al., 
1999). However, the limitations in application of this model have resulted in the decrease in 
its use in recent years. 
The EGSM was first described by Wilson and Wiseman (1954) to investigate the active 
transference of lactic acid, glucose and methionine across the intestinal wall, however a 
modified and improved EGSM by Barthe et al. (1998b) will be described. The EGSM 
involves the immediate excision of the small intestine from the abdominal cavity and from all 
afferent and efferent blood vessels, of an animal that has just been euthanased, with the rat 
the most commonly utilised species (Boüer et al., 1999). Following flushing with saline, the 
small intestine is carefully everted, sealed at one end with braided suture silk and filled with 
cold tissue culture medium, approximately at 6 °C. The intestine is then separated into 
segments approximately 2.5 cm in length also using braided suture silk. Each segment is then 
placed in a tank containing tissue culture medium, with each tank holding a known drug 
concentration in the external sac fluid. Each tank is aerated with 95% oxygen and 5% carbon 
dioxide. Tanks are incubated at 37 °C in an oscillating water bath. At the appropriate time 
points, which are variable between species (further described in Section 1.5), a volume of the 
external fluid is removed and the sacs are removed and rinsed with saline. The sacs are then 
cut open and serosal fluid is drained into small tubes for analysis.  
The EGSM is considered the preferential model for investigation of xenobiotic flux across 
the gut wall due to its minimal compromise of the intestinal wall, and remains relatively 
unchanged since Barthe et al.’s updated model in 1998. The use of a ‘broad spectrum’ tissue 
culture medium results in improved cellular metabolic activity, which prior to the 
development of this method was insufficient (Wilson, 1954, Barthe et al., 1998a). The 
intestinal wall is also maximally distended with tissue medium to maximise surface available 
for contact with administered drugs. These conditions, in association with the recommended 
warm temperature of 37 ºC, and aeration, mimic the body’s natural conditions and maximise 
the length of time before the validity of the tissue may be compromised (Wilson, 1954, 
Barthe et al., 1998a).  A more detailed discussion in assessment of the optimal and maximum 
incubation times are described in Section 1.5. 
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1.4 P-glycoprotein activity, and possible links to poor absorption 
P-glycoproteins (P-gp) are an extensively studied family of membrane-bound transporter 
proteins whose role is to actively expel toxins that may diffuse into cells (Thiebaut et al., 
1987). P-glycoproteins have a wide substrate specificity and are expressed in a number of 
tissues including the intestine, liver, renal tubular cells, brain and lymphocytes in a variety of 
species (Thiebaut et al., 1987). Specifically in the small intestines, P-gp is located on the 
apical membrane of mature intestinal cells and act as a pump to transport drugs back into the 
lumen as they are absorbed across the intestinal mucosa (Barthe et al., 1998a, Boüer et al., 
1999). P-glycoprotein activity and distribution appears to vary between species. In the horse, 
distribution of P-gp has been found to be very uneven, with significantly higher expression in 
the distal third of the duodenum and first quarter of the jejunum, compared to the rest of the 
intestine (Tydén et al., 2008). The rabbit has a similar distribution, although it stretches along 
the entire length of the duodenum and jejunum, but transporter protein distribution in the rat 
was significantly higher in the jejunum than duodenum or ileum (Pang, 2003). Gene-
expression of P-gp was also significantly increased in the liver of the horse compared to the 
rat (Tydén et al., 2008).  
P-glycoprotein is also known as multi-drug resistance protein (MDR-1). It has been 
hypothesised that this family of MDR-1 proteins may be responsible for reducing the 
bioavailability of medicines across a variety of surfaces throughout the body, such as the GIT 
of many species, including horses, dogs and people (Kuwazuru et al., 1990, Wacher et al., 
1998, Jonker et al., 1999, Smit et al., 1999, Tydén et al., 2008). These proteins are believed to 
be responsible for limiting the bioavailability of some orally given medicines by transporting 
them out of the body and back into the GIT for elimination (Ginn, 1996). However P-gp 
transport activity becomes saturated by high concentrations of medicine in the intestinal 
lumen (Lin and Yamazaki, 2003).   
The role of transporter proteins have been studied extensively in humans (Kuwazuru et al., 
1990), rats (Boüer et al., 1999, Varma et al., 2004) and horses (Tydén et al., 2008, Linardi et 
al., 2013), however there are many species for which the role of this protein has not been 
investigated. 
There are a wide range of currently recognised P-gp substrates, such as digoxin (DIG). These 
are substances that are known to interact with P-gp transporters, thereby facilitating the efflux 
of these medicines back into the intestinal lumen (Cavet et al., 1996). Therefore, many drugs 
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which are classed as P-gp substrates have significantly reduced oral bioavailability when 
compared to non-substrate drugs (Washington et al., 1998, Benet et al., 1999, Jonker et al., 
2000). P-gp substrates vary significantly in weight and structure, however the one common 
feature is that most P-gp substrates are hydrophobic (Lin and Yamazaki, 2003). 
Similarly, a wide range of substances known to inhibit P-gp activity are also recognised. 
Verapamil and quinidine are known to be in-vitro inhibitors of P-gp activity (Boüer et al., 
1999) and therefore enhance the transfer of P-gp substrates from the luminal surface to the 
serosa. Bouër et al. (1999) investigated the gut absorption of methadone at 5, 50 and 500 
µg/mL in Sprague-Dawley rats using the EGSM. The addition of both verapamil (100 µM) 
and quinidine (1.3mM) were found to increase the concentration of methadone that crossed 
the rat intestinal epithelium (Boüer et al., 1999). Of these drugs, quinidine was the most 
effective in increasing serosal concentration. Linardi (2013) demonstrated similar results by 
which the addition of verapamil significantly increased the absorption of methadone 
hydrochloride in an equine everted gut model.  
 
1.5 Historical improvements to the everted gut sac model 
Tissue viability is believed to be the main cause of compromised results when using the 
EGSM. Tissue collection is recommended to occur immediately following death (Wilson and 
Wiseman, 1954). The length of time between death and tissue removal is shown to 
significantly affect tissue viability, with studies demonstrating the transport of calcium and 
glucose were both significantly decreased in the intestinal segments of rats that were killed by 
cervical dislocation 10-20 minutes prior to tissue removal (Pento, 1988). Tissue viability 
within the duration of the model has also been questioned. The use of tissue culture medium 
instead of a salt buffer greatly increases the viability of the tissue and is considered a 
significant improvement on the basic model (Barthe et al., 1998a, Boüer et al., 1999). Barthe 
et al. (1998b) suggested rat tissue may remain viable under the recommended incubation 
conditions for up to a maximum of two hours. Following this time, histological analysis 
showed minimal disruption to the epithelial cells of the gut and maintenance of the junctions 
between the cells (Barthe et al., 1998b). The optimal length of incubation in the rat is usually 
therefore suggested at 60 minutes, to ensure the prevention of this cell trauma. This duration 
is, however, only recommended for the rat, and given the varying recommended incubation 
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periods in other species such as the horse, the maximum length of viability appears highly 
variable between species.  
Whilst the EGSM has been performed immediately following removal of the small intestine 
from the deceased animal, other experiments have found to have successfully cold stored the 
small intestine, with minimal effect on the tissue. Transplants of the duodenum and jejunum 
of the small intestine have been successfully completed with both rat and dog intestine, and 
are now a commonly used practice (Taguchi et al., 1989, Johnson et al., 2001). Following the 
removal of the intestine from the animal, the small intestine has been stored in a medium at 4 
ºC (Johnson et al., 2001). Taguchi et al. (1989) found that storage of the small intestine for up 
to 24 hours at 4 ºC resulted in similar muscle responses to that of controls, once the tissue 
was transplanted back into an animal. Similar results were found in relation to glucose, 
electrolytes and water absorbed across the small intestine (Watson et al., 1988). These results 
suggest that tissue may remain viable following cold storage under these conditions when the 
blood supply to the tissue is ultimately re-established, however the viability of the tissue has 
not been investigated in an in-vitro model with no blood supply.  
Incubation of everted gut sacs in the oscillating water bath when using rat intestine is 
suggested to be one hour in length, however the duration of incubation that results in least 
compromise of the tissue has been disputed (Wilson and Wiseman, 1954). Optimal length of 
incubation is also thought to vary between species, with an extended period of 120 minutes 
incubation preferred when studying transfer of substances across the intestinal epithelium of 
the horse (Linardi et al., 2013). The most common length of incubation time for use in the 
rabbit is one hour (Wilson and Lin, 1960), although a duration of  up to three hours has also 
been reported (Schachter, 1959). As the EGSM has not been investigated in marsupials, 
investigation into an optimal length of time of incubation is an important area for 
investigation. 
To assess tissue viability, the integrity of the sacs may be measured using glucose, a process 
first described by Dahlqvist (1968). As glucose is actively transported by the small intestine, 
metabolically active sacs will accumulate glucose in the serosal medium (Dahlqvist, 1968). 
The addition of glucose to the incubation medium and consequent comparison of glucose 
concentrations in the serosal and incubation mediums allows for assessment of the integrity 
of the sacs, and disregard of any results obtained from sacs that are deemed to be 
compromised. 
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The potential toxicity of different drugs may also compromise results using the EGSM. 
Excessive concentrations of metabolic toxins may be identified through changes in physical 
appearance, such as visible ulceration of the intestinal wall, however toxin concentrations 
sufficient to compromise results may not show any visible signs. Toxicity may be measured 
by assessing concentrations of the enzymes lactate dehydrogenase (LDH), the standard 
marker of cytotoxicity, and/or alkaline phosphatase (ALP) (Barthe et al., 1998a). The 
presence of these enzymes following incubation of the gut sac can signal compromise of the 
integrity of the sacs, which may influence the final results obtained. Unfortunately, there is 
no published data identifying the expected levels of either enzyme in the EGSM with any 
species. LDH concentrations were examined post-mortem from the liver and brain of rats that 
had been exposed to pesticides 24 hours prior to death, which had concentrations ranging 
from 76.9 – 79.2 U/L (Bagchi et al., 1995). It is expected, however, that concentrations seen 
in in-vivo and in-vitro experiments would vary greatly.  
There is also significant variation within previous studies using the everted gut sac model 
with respect to the intestinal section used. Whilst Barthe et al. (1998a) and Bouër et al. (1999) 
describe using the entire length of the small intestine, Varma et al. (2004) used only the 
ileum. However, it has also been hypothesised that most drug absorption would occur in the 
jejunum as it has the largest surface area (Pang, 2003). Despite this, studies have shown that 
absorption areas often differ between different classes of drugs and nutrients (Pansu et al., 
1983, Takashi et al., 1989), as well as being affected by gut contents (Sklan et al., 1973). 
Absorption of biotin along the small intestine has also been noted to be maximised in 
different locations in rats of different ages (Said et al., 1990). Despite all of these factors, 
when Barthe et al. (1998a) investigated the absorption of mannitol along the length of the 
small intestine, no significant differences in absorption were observed. As absorption varies 
so widely along the small intestine, using the entire length of the small intestine could 
provide highly variable results, however no investigation has standardised the optimal section 
of the small intestine for use in the EGSM. 
First pass metabolism is the process by which the concentration of some drugs is significantly 
limited before it reaches the circulatory system (Kwan, 1997). This loss is considered to 
occur due to processes in both the gut wall and liver. Whilst this model aims to quantify the 
effect of the intestinal wall, it does not consider the effect of the liver, and so is not an 
entirely accurate reflection of drug absorption in-vivo. 
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1.6 High performance liquid chromatography (HPLC) 
Following drainage of the serosal fluid, that drug concentration (not bound to proteinaceous 
material) in the serosal fluid and external tank fluid can be quantified using high performance 
liquid chromatography (HPLC) (McCreedy, 1997, Swadesh, 2001). Further, by optimising 
the liquid chromatography conditions, in some situations it is possible to quantify more than 
one drug at a time.   
The sample is suspended in a liquid state, referred to as the mobile phase, which passes 
through the HPLC column. Depending on the column characteristics, the drug is detected at a 
certain time, referred to as the retention time. A ‘detector’ registers and quantifies the drug as 
it comes off the column at the known retention time, and this information is used to create a 
chromatogram (Swadesh, 2001). The area under the sample peak is compared to a known 
standard curve, which is created from the assay of known concentrations of the target drug. 
From the known standard curve, the concentration of the unknown sample can be ascertained. 
This method has a very high level of specificity, good accuracy and adequate detection, 
making it preferential for use in association with the everted gut sac model. 
 
1.7 Overall objectives of this project 
Griffith et al.’s 2010 study established that when given orally, very small concentrations of 
some medicines are found to cross into the plasma of koalas, likely rendering the plasma 
concentrations sub-therapeutic. Whilst many of the hypotheses discussed above may 
contribute to this low bioavailability, the gut wall may also be acting as a barrier. Therefore 
to understand whether the gut wall contributes to this reduced bioavailability, the first step is 
to develop a model to observe the net flux of molecules across the gut wall. Such a model 
could be useful to compare the flux of different molecules for a single species study or 
consider the net flux of the same molecules across the gut of different species. The specific 
aims of this study are to develop and optimise the everted gut sac model, and use this to begin 
defining the role transporter proteins, specifically P-glycoproteins, play in the low 
bioavailability of orally dosed medicines. Another aim is to ascertain whether this model has 
application for use with marsupials as the attainment of ‘off-site’ fresh tissue from wildlife 
species can be problematic for the analytical laboratory.    
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The transfer of three target drugs (fluconazole [FLC], chloramphenicol [CHL] and digoxin 
[DIG]) will be investigated in this project as they display different structural and absorptive 
properties. Fluconazole is a hydrophilic antifungal medication that is commonly used in 
veterinary medicine (Silling, 2002), however has showed poor oral bioavailability when 
given to koalas (Black et al., 2014). Chloramphenicol is a lipophilic broad-spectrum 
antibiotic that has also shown to have low bioavailability when given both subcutaneously 
and intravenously to koalas (Govendir et al., 2011, Black et al., 2012), however due to its’ 
lipophilicity it is expected to cross cell membranes relatively easily. Digoxin  was selected as 
it is a recognised P-gp substrate, and is also a significantly larger molecular than the other 
two target drugs, with a molecular weight of 780.94 g/mol versus 306.27 and 323.12 g/mol of 
FLC and CHL, respectively (Greiner et al., 1999). 
 
1.8 Specific objectives of this project 
1. To optimise a chromatogram to be able to detect four drugs 
As four drugs (FLC, CHL, DIG and the internal standard) are required to be detected 
throughout the experimentation, this project will aim to optimise conditions to allow for all of 
these drugs to be detected in an appropriate amount of time on the same chromatogram in 
order to minimise experimental run time and reduce the number of animal tissues required.  
 
2. To optimise the rat EGSM 
As this project was our research group’s first experience with the EGSM, rat tissue will be 
used for the development of the prototype EGSM. This is because rat tissues can be 
opportunistically acquired on site within seconds of the animal being sacrificed for an 
unrelated project.  
Specifically the following will be investigated:  
- Whether there is a significant difference in transfer of FLC, CHL and DIG across the 
length of the small intestine, and if so, which sections of the gut display the highest 
transfer 
- What impact aeration with 95% oxygen : 5% carbon dioxide has on tissue viability, and 
therefore overall transfer 
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- How long tissue can be placed in cold storage whilst maintaining validity 
Following the optimisation of the gut sac model in the rat using cold stored tissue, the rate of 
transport of a known P-gp substrate, specifically DIG, as well as the hydrophilic FLC, and 
lipophilic CHL, across the GIT will be quantified. Drugs known to inhibit the activity of P-
gp, specifically verapamil, will also be added into the external sac fluid. The results obtained 
from the addition of this inhibitor will assist in our knowledge of the specific role of P-gps in 
transfer across the wall of the GIT.  
 
3. To investigate the viability of a possum EGSM 
Like the koala, possums are hindgut fermenters with large caecums, which is reflective of 
their unique eucalypt diet. Due to the similar physiology between marsupials, it is expected 
that the possum will provide a suitable model for use in the eventual target species, the koala.  
It will then be used to determine glucose transfer across the duodenum in the common 
ringtail possum and common brushtail possum as the project had access to fresh possum 
tissue. Once the model has been optimised for use with cold stored tissue, it is hoped that it 
will be able to be used to analyse the transfer of drugs across the intestinal wall of a number 
of species. 
The optimisation of this model to become suitable for use in a variety of species would allow 
for the in-vitro examination of drug transfer. The use of this model has the potential to 
identify a major limiting factor in the oral bioavailability of medicines in koalas, as gaining 
knowledge on the uptake of medicines across the GIT is critical to the oral therapeutic 
treatment of these species. This would allow for a solution to be investigated, and more long 
term, significantly decrease the number of live animals needed to test the oral absorption of 
medicines.  
 
4. Assessment of changes in cell integrity 
Lactate dehydrogenase (LDH) concentrations will be measured in both rat and possum 
models as an indicator of the extent of cell integrity. 
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2 Materials and methods 
2.1 Chemicals and materials 
Target drugs selected were FLC (hydrophilic and of small molecular weight) (Piscitelli et al., 
2011), CHL (lipophilic and of small molecular weight) (Lee and Desai, 2007) and DIG (a 
recognised P-gp substrate in both humans and animals, and of greater molecular weight) 
(Schinkel et al., 1995, Greiner et al., 1999).  Analytical grade FLC, CHL, DIG, florfenicol (as 
the internal standard [IS]) and tissue medium TCC199 (constituents of this tissue medium are 
provided in Appendix 1) were purchased from Sigma-Aldrich (Castle Hill, NSW). Analytical 
grade D-glucose was obtained from VWR International (Murarrie, QLD). HPLC-grade 
acetonitrile and methanol were supplied by Thermofisher Scientific (Scoresby, VIC). Purified 
water was obtained from a Milli-Q water system (Merck Millipore, Bayswater, VIC).  
2.2 High performance liquid chromatography (HPLC) materials and methods 
Drug concentration determination was performed by high performance liquid 
chromatography (HPLC).  
2.2.1 Chromatographic conditions 
The HPLC system consisted of a CBM-20A module (Shimadzu, Japan) equipped with a LC-
20AT delivery unit with a DGU-20AS degassing solvent delivery unit and SIL-20AC auto-
injector.  Chromatographic separation was initially performed using a Synergi C18, 4µm, 150 
x 4.6mm (Phenomenex, Lane Cove, NSW) attached to a 1-mm Opti-guard C-18 pre-column 
(Choice Analytical, Thornleigh, NSW). The column temperature was maintained at 30 ºC 
with a CTO-20AC column oven (Shimadzu, Japan). A method was developed by trial and 
error and modified over time in order to detect all four drug peaks of FLC, CHL, DIG and 
florfenicol as the internal standard (IS) on the one chromatogram. The isocratic mobile phase 
was composed of acetonitrile to water (25 : 75). The mobile phase was delivered at a flow 
rate of 1.0 mL/min, and injection volume was 10 µL. Results were measured at 216 nm, 
which was determined to be the wavelength at which all four drugs could be optimally 
measured together. Drug peaks were detected with an SPD-M20A diode array detector 
(Shimadzu, Japan) and a Shimadzu class VP data system (ver. 7.4; Shimadzu, Japan) was 
used for chromatographic control, data collection, and data processing.  
2.2.2 Preparation of standards and quality control (QC) samples 
Primary stock standard solutions of each drug (500 µg/mL) were prepared with the medium 
TCC199 and further diluted with TCC199 to obtain a series of working standard solutions of 
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0.25, 0.5, 1, 2.5, 5, 10, 25 and 50 µg/mL. Stock solutions were stored at 4º C and working 
standard solutions used to generate the calibration curves were freshly prepared from stock 
solutions for each analysis. Blank tissue medium was stored at 4º C and used for preparing 
the calibration standards and quality control (QC) samples. Three different concentrations of 
QC samples (1, 10 and 100 µg/mL) were used to monitor intra-assay and inter-assay 
variability and were prepared by spiking the blank tissue medium with the appropriate 
amount of working standard solutions and stored at 4º C until quantification. 
2.2.3 Calibration and sample preparations 
Known concentrations or calibration standards (ranging from 0.25, 0.5, 1, 2.5, 5, 10, 25 and 
50 µg/mL) were freshly prepared by spiking tissue medium with the working standard 
solutions. For preparation of the unknown experimental samples, incubated tissue medium 
was centrifuged at 1,400 x g for 10 minutes. Samples were then mixed in a 1:1 ratio with 200 
µL of the internal standard 5 mg/mL florfenicol. These samples were then centrifuged again 
at 1,400 x g for 5 minutes with the supernatant injected into the HPLC machine. 
 
2.2.4 Method validation 
Selectivity of the assay was measured by analysing blank tissue medium (n = 3) to evaluate 
interference around the retention times of each of the target drugs. Each drug plasma peak 
was identified individually using the described method, and therefore identified based on 
retention time. Target drug concentrations in samples were quantified according to the 
calibration curves for which eight drug concentrations (0.25, 0.5, 1, 2.5, 5, 10, 25 and 50 
µg/mL) were used to establish the non-weighted least square linear regression of the curve (y 
= ax + b). This was done by plotting the concentrations of the target drug (x) vs the peak area 
ratios (y) of target drug to IS where a and b represented the slope and y-intercept, 
respectively. Based on International Conference on Harmonisation for Human Use (ICH) 
guidelines (1996), the lowest limit of detection (LLOD) was determined based on calibration 
curves using the formula LLOD = 3.3 x σ/S, and the lowest limit of quantification (LLOQ) 
was determined based on calibration curves using the formula LLOQ = 10 x σ/S in which σ is 
the standard deviation (SD) of the y-intercepts for the regression lines and S is the mean slope 
of the calibration curves. An acceptance criterion for LLOD, LLOQ and all unknown 
concentrations was defined as precision less than 15% (coefficient of variation; CV 
[(SD/mean value) x 100]) and accuracy (otherwise referred to as ‘bias’ [(measured 
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concentration – nominal concentration) x 100]) within ± 20% of the nominal concentration 
with repeated analyses. 
Intra- and inter-day precision was analysed with triplicate QC samples (1, 10 and 100 µg/mL) 
within 1 day and before each batch run, respectively. Relative difference of the estimated 
concentrations was expressed as a percentage of the CV. 
 
2.3 Everted gut sac model materials and methods 
2.3.1 Tissue collection 
Rat tissue collection 
Rats were sourced from the Department of Neuropharmacology, The University of Sydney. 
Male Sprague-Dawley rats (Rattus norvegicus) between eight to thirteen weeks of age were 
obtained opportunistically from an unrelated research project and randomly provided. These 
rats had undergone surgical partial nerve ligation (PNL), as described by Seltzer et al. (1990), 
2.5 to 4 weeks prior to experimentation. Briefly, rats were anaesthetised, and the left sciatic 
nerve proximal to its trifurcation was exposed and a single suture was tied tightly around the 
nerve (Seltzer et al., 1990). This project presumed the surgery had minimal effect on the 
gastrointestinal tract. 
Rats were anaesthetised by enclosing them within a chamber containing isoflurane inhalation 
anaesthetic gas (Veterinary Companies of Australia, Kings Park, NSW). After two to three 
minutes, unconsciousness was confirmed and rats were euthanased by decapitation. The 
abdomen was then opened along the midline using scissors. The small intestine was exposed 
from the stomach to the caecum, and was excised using scissors. The small intestine was 
removed within 90 to 120 seconds following euthanasia. The intestines were then flushed 
using cold tissue medium, approximately 6 °C, and immediately placed into tissue medium 
kept on ice. Total time from euthanasia until the intestines were placed on ice was less than 4 
minutes.  
Possum tissue collection 
All possum tissue obtained for this study was collected opportunistically from St Ives 
Veterinary Surgery (7/351 Mona Vale Rd, St Ives, NSW). All possums recruited were 
deemed unfit for rehabilitation by the veterinarians and that euthanasia was the only humane 
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course of action. Therefore, both common ringtail possums and common brushtail possums, 
both males and females and a range of ages were recruited for this study. For each possum, 
the gender and reason for euthanasia was recorded. Age was approximated through dentition 
(Winter, 1980, Cowan and White, 1989). 
Possums were euthanased using 1-2 mL/kg of sodium pentobarbitone (325 mg/mL) 
(Lethabarb, Virbac Animal Health) diluted 50:50 with warm water to 2.5 mL, which was 
injected directly into the liver, resulting in unconsciousness within 10-30 seconds. A scalpel 
incision was made immediately following pupil dilation, and the small intestines were 
removed within 60 to 90 seconds. This euthanasia protocol was approved by The University 
of Sydney Animal Ethics Committee (Protocol number N009-2013-3-6062). 
 
2.3.2 Tissue storage and preparation 
Storage 
Following their removal immediately following euthanasia, the small intestine of both the rat 
and possum were rinsed with rinsed with cold tissue medium (TCC199). 
Tissue preparation of the majority of rat intestines was performed within 60 minutes of tissue 
collection, during which time the tissues were placed in medium and refrigerated at 4 ºC. In 
preparation for Experiment 2 (0.5 vs 24 hour storage), the intestines of five rats were placed 
in tissue medium and refrigerated at 4 ºC for 24 hours prior to preparation. 
Tissue preparation of each possum intestine was performed 24 hours after collection, due to 
time limitations. During this time, tissue was refrigerated in medium at 4 ºC. 
Preparation of everted gut sacs in medium 
Throughout the preparation time, the tissues were kept on ice. 
The small intestine was removed from the stomach to the caecum. Rat intestine was threaded 
over a straw, and inverted using tweezers. Possum tissue was carefully inverted by hand, 
using tweezers. The tissue was then secured at the end using suture silk, and cold tissue 
medium was pipetted into the inside of the intestine. Individual sacs were then formed by 
securing the intestines with suture silk. Each length of suture silk had an identifying number 
of knots tied in it, to allow for identification of each segment. Sacs were 2.5 to 3 cm in 
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length, resulting in an internal volume of approximately 2.5 mL of medium in possums, and 
0.6 mL in rats. Sacs were then separated and put back into tissue medium on ice until 
incubation, which was no longer than 20 minutes. 
2.3.3 Tissue incubation 
Tissue medium (TCC199) in a beaker (referred to as the ‘tissue tank’) was heated in a gently 
oscillating water bath (Ratek, Boronia, VIC) maintained at 37.2 ºC. Initial tissue medium 
volume was dependent on final required drug concentration. Aeration by Carbonox gas (95% 
oxygen and 5% carbon dioxide; Coregas, Yennora, NSW) into each tissue tank was 
facilitated via a narrow bore plasticised tube. Individual gut sacs were introduced and 
incubated in the warm medium for 10 minutes. Following this time, the target drug/s were 
added to the incubating medium, to bring the final fluid volume to 100 mL for rat sacs, and 
200 mL for possum sacs incubation due to size differences of the intestinal sacs between 
species. This apparatus is illustrated in Figure 1. 
 
Figure 1. Incubation set up of the everted gut sac model. (a) aeration tube, (b) tissue medium 
containing target drug, (c) individual everted gut sacs, (d) tissue tank, (e) heating water bath. 
At the end of the desired incubation time, gut sacs were individually removed and gently 
blotted dry manually. A small incision was then made in the bottom of the gut sac, and the 
contents of each sac were then drained into a separate Eppendorf tube. The amount drained 
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from each individual sac using rat tissue ranged from 0.4 to 0.7 mL. The sac weight before 
and after draining was not recorded. A sample of 0.5 mL of fluid remaining in the tank was 
removed after incubation to determine drug concentration in the external medium. 
 
2.4 Drug stability throughout incubation 
In order to establish whether any degradation of the target drugs occurred throughout the 
incubation period, 6.5 µg/mL of each drug was incubated in 50 mL tissue medium without 
the presence of gut sacs. This concentration of each drug was chosen prior to the final 
determination of the target experimental concentration to be examined, and so unfortunately 
differed from the final experimental concentration used. Three samples of 0.5 mL were taken 
from the tank every 10 minutes for 60 minutes.  
 
2.5 EGSM experimental design 
2.5.1 Experiment 1. Comparison of proportion of drug transferred along the length of 
the small intestine 
Various sections of the small intestine have been used in the EGSM. It has been hypothesised 
that highest transfer would occur in the jejunum, as it has the largest mucosal surface area 
(Pang, 2003), however different xenobiotics have been known to be transferred in different 
areas along the small intestine, particularly the transfer of significant nutrients such as 
calcium, iron and vitamin D in the duodenum (Pansu et al., 1983, Takashi et al., 1989). 
Experiment 1 was designed to investigate whether a significant difference in transfer 
occurred along the length of the small intestine. 
The entire length of the small intestine was divided into four equal quarters in length. Three 
gut sacs were made sequentially from each of the four quarters of the length of the small 
intestine. Following the 10 minute initial incubation period, FLC, DIG and CHL dissolved in 
tissue medium were added to the same tissue tank, to bring the final concentration of each 
drug to 25 µg/mL. Three sacs were obtained from each of the four quarters of the intestine, 
resulting in a total of 12 sacs from each rat. This was repeated for each individual rat. The gut 
sacs were then incubated for the total time of 60 minutes. The total number of sacs incubated 
from each quarter is provided in Table 1. 
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Table 1. Total number of gut sacs incubated from each quarter with 25 µg/mL FLC, CHL and 
DIG(number of rats used to obtain these sacs). Quarter is abbreviated to Q.  
Quarter Total number of gut 
sacs incubated  
Q1 9 (3) 
Q2 9 (3) 
Q3 9 (3) 
Q4 9 (3) 
 
For experiments 1 to 6 the respective drug concentration (FLC, CHL and DIG) of the tissue 
medium external and internal to the gut sacs was compared as the proportion of drug 
transferred across the gut wall. This was determined as: 
% transfer = (internal concentration at time of removal of sac from tank / external 
concentration at time of removal of sac) * 100 
 
2.5.2 Experiment 1a. Comparison of proportion of drug transfer across Q1 
Based on results from Experiment 1 (see Results Section 3.3.1), segments from Q1 were then 
examined to determine whether there was a significant difference in transfer along this 
quarter. 
From each of three rats, the entire length of Q1 was segmented, resulting in five individual 
gut sacs. Sacs were numbered sequentially from the cranial to caudal segments. These gut 
sacs were incubated for 60 minutes, with a concentration of 25 µg/mL each of FLC, CHL and 
DIG in the tank. The transfer seen in each of these segments was analysed in order to 
determine whether there was a significant difference in transfer seen between segments of 
Q1. The total number of sacs incubated at each time point is provided in Table 2. 
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Table 2. Total number of gut sacs incubated from along the length of Q1 with 25 µg/mL FLC, 
CHL and DIG (number of rats used to obtain these sacs).  
Segment  Total number of gut 
sacs incubated 
S1 3 (3) 
S2 3 (3) 
S3 3 (3) 
S4 3 (3) 
S5 3 (3) 
 
2.5.3 Experiment 2. Comparison of proportion of glucose transferred with respect to 
tissue duration in cold storage.  
This experiment was designed to investigate whether there was a significant difference 
between the transfer seen when tissue was stored for a short duration (0.5 hours) versus a 
longer duration (24 hours), both at 4 ºC. This was to investigate the length of time the tissue 
would be viable in cold storage. 
Three Q1 gut sacs from six rats (see Results Section 3.3.1 and 3.3.2) were incubated 
following the normal cold storage period between excision of tissue and formation of gut 
sacs, which averaged 0.5 hours. Three Q1 gut sacs from the same location from another five 
rats were incubated following extended cold storage at 4 ºC in tissue medium for a length of 
22 to 24 hours. Following the 10 minute initial incubation time, D-glucose pre-dissolved in 
tissue medium was added to the tissue tank to bring the final concentration to 3.6 mg/L. Gut 
sacs were incubated for a total of 60 minutes. The total number of gut sacs stored for each 
period of time is provided in Table 3. 
 
Table 3. Total number of gut sacs incubated at 0.5 hours cold storage vs 24 hours cold 
storage (number of rats used to obtain these rats).  
0.5 hours cold storage 24 hours cold storage 
18 (6) 15 (5) 
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2.5.4 Experiment 3. Investigation into effect of aeration of tissue medium on glucose 
transfer 
This experiment was designed to investigate the effect aeration (95% oxygen and 5% carbon 
dioxide) has on the viability of the gut sacs. This was done by investigating the difference in 
transfer seen with and without aeration of the tissue medium. 
Three Q1 gut sacs (see Results Section 3.3.1 and 3.3.2) from four rats were incubated in 
aerated tissue medium and three Q1 gut sacs from another four rats were incubated in tissue 
medium without the presence of aeration. Following the 10 minute initial incubation time, D-
glucose pre-dissolved in tissue medium was added to the tissue tank to bring the final 
concentration to 8 µg/mL. Gut sacs were incubated for a total of 60 minutes. The total 
number of gut sacs incubated in each tissue tank is provided in Table 4. 
 
Table 4. Total number of gut sacs incubated with aeration and without aeration (number of 
rats used to obtain these sacs). 
Total gut sacs 
incubated with 
aeration 
Total gut sacs 
incubated 
without aeration 
12 (4) 12 (4) 
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2.5.5 Experiment 4. Comparison of proportion of transfer of three target drugs 
simultaneously across the small intestine 
Three drugs with different chemical and physical properties were selected. Due to these 
different properties, it was expected that the proportion of each drug transferred across the 
gut wall may differ. 
Following a 10 minute initial incubation period, FLC, CHL and DIG (pre-dissolved in tissue 
medium), were added to the same tissue tank to bring the final concentration of each drug to 
25 µg/mL. Tissue sacs from three rats at Q1 (see Results Section 3.3.1 and 3.3.2) were each 
incubated for the following durations: 5, 10, 15, 20, 30, 45 and 60 minutes, before being 
removed from the tissue tank. The number of gut sacs varied depending on size of the rat and 
was also limited by the formation of holes in the small intestine. The total number of sacs 
incubated at each time point is provided in Table 5. 
 
Table 5. Total number of gut sacs incubated at each time duration with 25 µg/mL FLC, CHL 
and DIG (number of rats used to obtain these sacs). 
Duration of 
incubation 
(minutes) 
Total number of gut 
sacs incubated 
5 15 (3) 
10 22 (4) 
15 16 (3) 
20 16 (3) 
30 15 (3) 
45 17 (3) 
60 17 (3) 
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2.5.6 Experiment 5. Effect of a P-gp inhibitor drug on the proportion of transfer of the 
three target drugs 
Following from Experiment 4, a drug known to inhibit the activity of P-gp, verapamil 
(Wandel et al., 1999), was added into the incubation tank, to investigate the effect on 
proportion of drug transfer. 
All gut sacs were taken from Q1 (see Results Section 3.3.1 and 3.3.2). Following the 10 
minute initial incubation period, FLC, CHL and DIG dissolved in tissue medium were added, 
to bring the final concentration of each to 25 µg/mL. Two different concentrations of 5 
µg/mL and 25 µg/mL verapamil were also added to separate tanks. Quadrant one tissue sacs 
from two rats were each incubated at each time point of 5, 10, 15 and 20 minutes with each 
concentration of verapamil, using a total of 16 rats. These were separate to the rats used in 
Experiment 4. The number of gut sacs varied from five to six depending on size of the rat and 
was limited by the formation of holes in the small intestine, resulting in a total of 10 to 12 gut 
sacs incubated at each time point. The total number of sacs incubated at each time point is 
provided in Table 6.  
 
Table 6. Total number of gut sacs incubated at each time point with 25 µg/mL FLC, CHL, 
DIG and the inclusion of verapamil (number of rats used to obtain these sacs).  
Minutes Total number of sacs 
incubated w/  
5µg/mL verapamil 
Total number of sacs 
incubated w/  
25µg/mL verapamil  
 
5 0 0 
10 12 (2) 12 (2) 
15 12 (2) 10 (2) 
20 12 (2) 11 (2) 
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2.5.7 Experiment 6.  Proportion of glucose transferred across possum small intestine 
As discussed in Section 1.1, it has been suggested that marsupials may not absorb some 
xenobiotics at the same rate as other species (Eason et al., 1994, Griffith et al., 2010, Kimble 
et al., 2013). Experiment 6 was designed to measure base glucose transfer in the possum. 
Since the everted gut sac model has not been validated for use in marsupials, the proportion 
of glucose transfer at three different time points were investigated. 
All examined gut sacs were taken from Q1 (see Results Section 3.3.1 and 3.3.2). Following 
the 10 minute initial incubation period, D-glucose dissolved in tissue medium was added to 
the incubating medium, to bring the final D-glucose concentration to 1.8 mg/L. Tissue 
samples from each possum were incubated for either 30, 60 or 90 minutes, following which 
time they were removed. Possums were numerically identified chronologically. The total 
number of gut sacs incubated at each time point is provided in Table 7. Table 8 describes the 
species, age, gender and reason for euthanasia for each of the possums sourced for this study. 
Possums were numbered progressively as they were sourced. 
 
Table 7. Total number of possum Q1 gut sacs incubated at each time point. In brackets, the 
number of possums sacrificed to obtain these sacs. 
 Total number of brushtail 
possum sacs incubated 
Total number of ringtail 
possum sacs incubated 
Total 
Minutes Male Female Male Female  
30 18 (2) 0 8 (1) 0 26 (3) 
60 8 (1) 8 (1) 0 7 (1) 23 (3) 
90 0 30 (3) 0 9 (1) 39 (4) 
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Table 8. Summary of possums sourced for this thesis. 
Possum 
ID no. 
Species Age Sex Reason for euthanasia Incubation 
period 
(minutes) 
1 Ringtail Subadult Female Injuries possibly sustained 
from dog 
60 
2 Brushtail Subadult Female Unknown neurological issue 60 
3 Brushtail Adult Female Dermatitis, fleas, general 
poor health 
90 
4 Ringtail Elderly Female Burnt paws, malnourished 90 
5 Ringtail Adult Male Unknown neurological issue 30 
6 Brushtail Elderly Male Cachetic 30 
7 Brushtail Adult Male Cachetic 60 
8 Brushtail Adult Female Cachetic, malnourished 90 
9 Brushtail Elderly Female Cachetic, large abscess on 
face  
90 
10 Brushtail Subadult Male Necrotic paw syndrome 30 
 
 
2.5.8 Experiment 7. Lactate dehydrogenase stability 
Lactate dehydrogenase (LDH) concentration can be used as a marker of cytotoxicity, which 
can signal compromise of the integrity of the tissue used in the gut sacs (Barthe et al., 1998a). 
These concentrations were recorded to investigate cell toxicity. Samples (0.5 mL) of the 
internal and external medium from one rat obtained at each time point of Experiment 4 were 
tested for LDH activity by the Veterinary Pathology Diagnostic Services (VPDS) of The 
University of Sydney. The rat tested was chosen randomly. All testing for LDH was 
performed on the day of the gut sac incubation. 
Samples (0.5 mL) were taken from all possums in Experiment 6 (except possum 1), and were 
also tested for LDH. All segments were tested. All samples obtained from possums were also 
tested for LDH on the day the tissue was incubated. 
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2.6 Statistical analyses 
Each assay was conducted in triplicate. The data for Experiments 1 to 3 were analysed using 
Graph Pad Prism for Windows (ver. 5.01; Graph Pad Software, USA). The data for 
Experiments 4 and 5 was analysed using GenStat for Windows (17
th
 Edition; VSN 
International, UK). P-values < 0.05 were considered statistically significant. 
 
Experiment 1 & 1a  
Data was analysed using a 2-way ANOVA. Data was analysed for significant differences in 
drug transfer between each quarter, and each individual rat, as well as for differences along 
the length of Q1. 
Experiment 2 
Data was analysed using unpaired two tailed t-tests. Data was analysed for significant 
differences in mean glucose transfer between tissue that had been stored at 4 ºC for 0.5 hours 
and tissue that had been stored at 4ºC for 24 hours. Based on results from Experiment 1a, all 
segments along Q1 were grouped together for statistical analysis. 
Experiment 3 
Data was analysed using unpaired two tailed t-tests. Data was analysed for significant 
differences in mean glucose transfer between tissue that had been incubated with and without 
the presence of Carbonox (95% oxygen : 5% carbon dioxide). Based on results from 
Experiment 1a, all segments along Q1 were grouped together for statistical analysis. 
Experiment 4 
An unbalanced ANOVA was used to analyse differences between the drugs at the time points 
of 5, 10, 15 and 20 minutes, as well as to look for an interaction between drugs over time. 
Based on results from Experiment 1a, all segments along Q1 were grouped together for 
statistical analysis. 
Experiment 5 
An unbalanced ANOVA was used to analyse differences between the drugs at the time points 
of 5, 10, 15 and 20 minutes with the inclusion of two concentrations of verapamil, as well as 
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to look for an interaction between drugs over time. The same analysis was also used to 
investigate whether there were any significant differences in transfer of each drug with the 
two examined concentrations of verapamil, versus the results seen in Experiment 4 with no 
verapamil. Based on results from Experiment 1a, all segments along Q1 were grouped 
together for statistical analysis. 
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3 Results 
3.1 HPLC 
3.1.1 Chromatographic separation 
Based on the UV spectra, the optimal wavelength was set at 216 nm for quantitative analysis 
of the three target drugs. The retention times of FLC, florfenicol as the internal standard (IS), 
CHL and DIG were 2.7, 5.2, 6.3 and 11.1 minutes, respectively. All drug peaks were well 
resolved and no endogenous interference was observed.  
A typical chromatogram of tissue medium spiked with FLC (25 µg/mL), IS (5 µg/mL), CHL 
(25 µg/mL) and DIG (25 µg/mL) is illustrated in Figure 2.  
The column used was a Synergi C18, 4µm, 150 x 4.6mm (Phenomenex, Lane Cove, NSW) 
attached to a 1-mm Opti-guard C-18 pre-column (Choice Analytical, Thornleigh, NSW). This 
column was found to provide the best sensitivity and peak resolution for all target drugs. 
Table 9 contains a list of other columns that were tested but proved less successful in peak 
separation. Acetonitrile : water (25 : 75) was selected as the organic modifier of the mobile 
phase as this reagent produced minimal base-line noise compared to methanol. All peaks 
were resolved in less than 13 minutes. 
Analysis of a contour graph (as illustrated in Figure 3) demonstrates the peak wavelength for 
detection of all drugs was 216 nm. 
Table 9. Less successful trialled columns 
Trialled columns 
Luna C18, 5µ, 250 x 4.6 mm (Phenomenex, Lane Cove, NSW) 
Novapak C18, 4µ, 3.9 x 300 mm (Waters, Rydalmere, NSW) 
Alltima C18, 5µ, 250 x 4.6 mm (Alltech, Dandenong South, VIC) 
Apollo C18, 5µ, 250 x 4.6 mm (Alltech, Dandenong South, VIC) 
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Figure 2. Chromatogram of target drugs. Peaks displayed are FLC (2.7 mins), florfenicol (5.2 mins), CHL (6.3 mins) and DIG (11.1 mins). The 
wavefront is the commencement of detection of the injected sample volume.  
Fluconazole 
Florfenicol (IS) 
Chloramphenicol 
Digoxin 
Wavefront 
40 
 
 
Figure 3. Contour graph of target drugs. Peaks displayed are FLC (2.6 mins), florfenicol (5.1 mins), CHL (6.2 mins) and DIG (11.3 mins). 
Green line indicates wavelength of 216 nm.
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3.1.2 Validation of HPLC 
Linearity, sensitivity, precision, accuracy 
The mean regression calibration curve of FLC (based on three curves) were expressed as y = 
4.7484 (± 0.1109, SD) x + 33.2847 (± 1.1855, SD) with the correlation coefficient (r
2
) for 
each curve greater than 0.9983. Based on the SD of the y-intercept and slope of the curve, the 
lowest limit of detection (LLOD) for FLC was estimated to be 0.82 µg/mL and lowest limit 
of quantification (LLOQ) was estimated to be 2.50 µg/mL  
Precision and accuracy determined for FLC QC samples (2.5, 10 and 100 µg/mL) are 
summarised in Table 10. A concentration of 1 µg/mL was not used as for CHL and DIG as it 
was below the lowest limit of quantification for this drug. 
 
Table 10. Precision and accuracy of FLC QC samples (triplicates per day, 3 over 5 days). 
Nominal 
concentration 
(µg/mL) 
Mean ± SD measured 
concentration µg/mL) 
Precision (CV %) Accuracy (Bias %) 
Intraday Interday Intraday Interday Intraday Interday 
LLOQ (2.5) 2.52 ± 0.04 2.48 ± 0.04 1.42 1.53 0.80 -0.80 
10 9.96 ± 0.40 10.08 ± 0.30 4.00 3.01 -0.40 0.80 
100 99.65 ± 1.48 98.52 ± 1.82 1.48 1.85 -0.35 -1.48 
 
The mean regression calibration curve of CHL (based on three curves) was expressed as y = 
15.603 (± 0.2226, SD) x + 2.0762 (± 1.0442, SD) with the correlation coefficient (r
2
) for each 
curve greater than 0.9999. Based on the SD of the y-intercept and slope of the curve, the 
LLOD for CHL was estimated to be 0.22 µg/mL and LLOQ was estimated to be 0.67 µg/mL. 
Precision and accuracy determined for CHL QC samples (0.67, 1, 10 and 100 µg/mL) are 
summarised in Table 11. 
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Table 11. Precision and accuracy of CHL QC samples (triplicates per day, 3 over 5 days). 
Nominal 
concentration 
(µg/mL) 
Mean ± SD measured 
concentration (µg/mL) 
Precision (CV %) Accuracy (Bias %) 
Intraday Interday Intraday Interday Intraday Interday 
LLOQ (0.67) 0.62 ± 0.02 0.61 ± 0.02 2.47 2.67 -7.46 -8.96 
1 1.13 ± 0.02 1.04 ± 0.01 1.78 1.39 13.00 4.00 
10 10.19 ± 0.23 9.69 ± 0.20 2.29 2.11 1.90 -4.00 
100 101.67 ± 
0.29 
101.71 ± 
0.49 
0.29 0.48 1.67 1.71 
 
The mean regression calibration curve of DIG (based on three curves) was expressed as y = 
11.398 (± 0.2006, SD) x + 0.6673 (± 0.3188, SD) with the correlation coefficient (r
2
) for each 
curve greater than 0.9996. Based on the SD of the y-intercept and slope of the curve, the 
LLOD for DIG was estimated to be 0.09 µg/mL and the LLOQ for DIG was estimated to be 
0.28 µg/mL. 
Precision and accuracy determined for DIG QC samples (0.28, 1, 10 and 100 µg/mL) are 
summarised in Table 12. 
 
Table 12. Precision and accuracy of DIG QC samples (triplicates per day, 3 over 5 days). 
Nominal 
concentration 
(µg/mL) 
Measured concentration 
(µg/mL) 
Precision (CV %) Accuracy (Bias %) 
Intraday Interday Intraday Interday Intraday Interday 
LLOQ (0.28) 0.27 ± 0.01 0.27 ± 0.01 3.16 3.01 -3.57 -3.57 
1 1.08 ± 0.02 1.04 ± 0.03 1.65 2.62 8.00 4.00 
10 9.94 ± 0.16 9.90 ± 0.12 1.62 1.24 -0.60 -1.00 
100 99.23 ± 0.79 99.31 ± 0.83 0.79 0.84 -0.77 -0.69 
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3.2 Drug degradation and stability  
Summary statistics of the mean change in concentration of the target drugs throughout 60 
minutes of incubation in tissue medium, without tissue, are shown in Table 13. Sampling was 
conducted every 10 minutes from 0 to 60 minutes, resulting in a total of seven measurements. 
The drug was assessed to be stable when the CV was less than 20%. 
 
Table 13. Summary statistics of the degradation of target drugs in tissue medium over 60 
minutes. 
 FLC CHL DIG 
Concentration t0 
(µg/mL) 
6.32 5.99 6.69 
Mean concentration 
from 0-60 minutes ± 
SD (µg/mL) 
6.22 ± 0.24 5.97 ± 0.20 6.62 ± 0.22 
CV (%) 3.82 3.34 3.25 
 
Therefore all three drugs were classed as stable over 1 hour, and had good precision (CV% 
3.25 to 3.82 %). 
 
3.3 EGSM incubation experiments 
3.3.1 Experiment 1: Comparison of proportion of drug transferred along the length of 
the small intestine 
Tables 14, 15 and 16 summarise the mean ± SD and the range of proportion of drug 
transferred following 60 minutes of incubation across the entire length of the small intestine 
of FLC, CHL and DIG, respectively.  
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Table 14. Summary statistics for transfer of FLC across the entire length of the small 
intestine following 60 mins. n = number of gut sacs. 
  Rat 1 Rat 2 Rat 3 Mean FLC 
transfer ± SD 
Q1 n 3 3 3  
78.80 ± 6.54 Mean ± SD 85.48 ± 0.45 72.95 ± 1.96 77.96 ± 6.90  
Range (min-max) 85.10 – 85.98 71.13 – 75.04 70.26 – 83.59 
Q2 n 3 3 3  
55.21 ± 7.44 Mean ± SD 60.51 ± 4.18 57.27 ± 8.59 47.86 ± 0.94 
Range (min-max) 55.88 – 64.01 48.21 – 65.28 47.21 – 48.93 
Q3 n 3 3 3  
46.12 ± 16.68  Mean ± SD 66.63 ± 4.30 42.27 ± 1.89 29.45 ± 4.59 
Range (min-max) 61.78 – 70.01 41.14 – 44.45 24.88 – 34.05 
Q4 n 3 3 3  
54.29 ± 10.19 Mean ± SD 62.19 ± 0.77 50.38 ± 2.13 50.29 ± 16.44 
Range (min-max) 61.54 – 63.05 47.98 – 51.13 34.83 – 67.56 
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Table 15. Summary statistics for transfer of CHL across the entire length of the small 
intestine following 60 mins. n= number of gut sacs. 
  Rat 1 Rat 2 Rat 3 Mean CHL 
transfer ± SD  
Q1 n 3 3 3  
84.37 ± 6.83 Mean ± SD 83.48 ± 0.98 80.42 ± 9.73 89.20 ± 5.60 
Range (min-max) 82.37 – 84.23 74.06 – 91.61 82.87 – 93.53 
Q2 n 3 3 3  
63.50 ± 11.03 Mean ± SD 75.92 ± 7.11 61.21 ± 6.30 53.37 ± 1.86 
Range (min-max) 69.38 – 83.49 54.10 – 66.10 51.75 – 55.40 
Q3 n 3 3 3  
57.25 ± 11.03 Mean ± SD 73.46 ± 4.08 57.44 ± 0.54 40.85 ± 6.03 
Range (min-max) 68.74 – 75.83 56.86 – 57.91 34.20 – 45.94 
Q4 n 3 3 3  
63.10 ± 9.53 Mean ± SD 75.12 ± 2.08 57.59 ± 3.92 56.58 ± 4.23 
Range (min-max) 73.51 – 77.46 54.89 – 62.09 51.70 – 59.20 
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Table 16. Summary statistics for transfer of DIG across the entire length of the small 
intestine following 60 mins. n= number of gut sacs.  
  Rat 1 Rat 2 Rat 3 Mean DIG 
transfer ± SD  
Q1 n 3 3 3  
63.48 ± 6.37 Mean ± SD 62.12 ± 1.46 60.67 ± 7.45  67.64 ± 7.99 
Range (min-max) 60.44 – 63.14 55.11 – 69.14 59.14 – 75.00 
Q2 n 3 3 3  
42.98 ± 8.24 Mean ± SD 52.16 ± 2.12 42.76 ± 3.79 34.01 ± 2.39 
Range (min-max) 49.71 – 53.49 38.38 – 45.09 32.08 – 36.69 
Q3 n 3 3 3  
37.44 ± 11.68 Mean ± SD 50.20 ± 3.86 37.73 ± 1.12 24.40 ± 5.46  
Range (min-max) 45.76 – 52.77 36.45 – 38.53 18.68 – 29.57 
Q4 n 3 3 3  
43.90 ± 9.07 Mean ± SD 49.64 ± 5.41 38.28 ± 3.51 43.78 ± 13.82 
Range (min-max) 44.80 – 55.48 34.34 – 41.04 32.23 – 59.09 
 
The transfer of FLC in Q1 was significantly higher than Q2, Q3 and Q4 in all rats (as 
demonstrated in Table 17, and illustrated in Figure 4). There was also a significant difference 
in transfer between Q2 and Q3 in Rat 2 and Rat 3 (P ≤ 0.05 and P ≤ 0.01, respectively). There 
was a significant difference in transfer between Q3 and Q4 in Rat 3 only (P ≤ 0.01). 
Table 17. Statistical significance of comparative FLC transfer across entire length of the 
small intestine. * describes P ≤ 0.05, ** describes P ≤ 0.01, *** describes P ≤ 0.001, **** 
describes P ≤ 0.0001. n.s. signifies non significance.   
 Rat 1 Rat 2 Rat 3 
Q1 vs Q2 *** * **** 
Q1 vs Q3 ** **** **** 
Q1 vs Q4 *** *** **** 
Q2 vs Q3 n.s. * ** 
Q2 vs Q4 n.s. n.s. n.s. 
Q3 vs Q4 n.s. n.s. ** 
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Figure 4. Column graph illustrating the mean and standard deviation of proportion transfer 
of FLC across each quarter of the entire length of the small intestine following 60 mins. 
 
The transfer of CHL shown in Q1 was significantly different to Q2, Q3 and Q4 in Rat 2 and 
Rat 3 (as demonstrated in Table 18 and illustrated in Figure 5). Rat 3 also displayed 
significant differences in transfer between Q2 and Q3, and Q3 and Q4 (P ≤ 0.05 and P ≤ 0.01, 
respectively). There were no significant differences between any quarters of Rat 1. 
 
Table 18. Statistical significance of comparative CHL transfer across entire length of the 
small intestine. * describes P ≤ 0.05, ** describes P ≤ 0.01, *** describes P ≤ 0.001, **** 
describes P ≤ 0.0001. n.s. signifies non significance.   
 Rat 1 Rat 2 Rat 3 
Q1 vs Q2 n.s. *** **** 
Q1 vs Q3 n.s. **** **** 
Q1 vs Q4 n.s. **** **** 
Q2 vs Q3 n.s. n.s. * 
Q2 vs Q4 n.s. n.s. n.s. 
Q3 vs Q4 n.s. n.s. ** 
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Figure 5. Column graph illustrating the mean and standard deviation of proportion transfer 
of CHL across each quarter of the entire length of the small intestine following 60 mins. 
 
The transfer of DIG shown in Q1 was significantly different to Q2, Q3 and Q4 in Rat 2 and 
Rat 3 only (as demonstrated in Table 19, and depicted in Figure 6). Rat 3 also displayed 
significant differences in transfer between Q3 and Q4 (P ≤ 0.01). There were no significant 
differences between any quarters of Rat 1. 
Table 19. Statistical significance of comparative DIG transfer across entire length of the 
small intestine. * describes P ≤ 0.05, ** describes P ≤ 0.01, *** describes P ≤ 0.001, **** 
describes P ≤ 0.0001. n.s. signifies non significance.   
 Rat 1 Rat 2 Rat 3 
Q1 vs Q2 n.s. ** **** 
Q1 vs Q3 n.s. *** **** 
Q1 vs Q4 n.s. *** *** 
Q2 vs Q3 n.s. n.s. n.s. 
Q2 vs Q4 n.s. n.s. n.s. 
Q3 vs Q4 n.s. n.s. ** 
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Figure 6. Column graph illustrating the mean and standard deviation of proportion transfer 
of DIG across each quarter of the entire length of the small intestine following 60 mins. 
 
The quarter of the small intestine was significant in influencing the proportion of FLC, CHL 
and DIG transferred into the gut sacs (P < 0.0001, P < 0.0001 and P = 0.0003 respectively). 
There was greatest difference in Q1 compared to the other quadrants with all rats and all 
drugs. The individual rat was also significant in influencing the transfer of all three target 
drugs into the gut sacs (P < 0.0001 for all), with all three drugs being studied in the same 
three rats. There was also a significant interaction between these two factors in the transfer of 
all three target drugs (FLC, P = 0.005; CHL, P < 0.0001; DIG, P = 0.0035). 
 
3.3.2 Experiment 1a: Comparison of proportion of drug transfer across Q1 
Table 20 shows a summary of the mean ± SD of proportion of drug transferred across 
segments along the entire length of Q1 following 60 minutes of incubation. These data sets 
are displayed in Figures 7, 8 and 9.  
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Table 20. Summary statistics for percentage transfer of FLC, CHL and DIG across the entire 
length of Q1 following 60 mins. n= number of gut sacs. 
  FLC CHL DIG 
S1 n 3 3 3 
Mean ± SD 81.12 ± 2.70 78.67 ± 2.57 64.67 ± 9.95 
Range (min-max) 79.17 – 84.20 76.80 – 81.59 57.98 – 76.11 
S2 n 3 3 3 
Mean ± SD 82.17 ± 4.40 79.44 ± 7.41 66.52 ± 13.99 
Range (min-max) 78.46 – 87.03 71.93 – 86.75 53.90 – 81.56 
S3 n 3 3 3 
Mean ± SD 76.78 ± 11.51 81.85 ± 4.58 68.59 ± 8.25 
Range (min-max) 69.55 – 90.05 76.62 – 85.17 61.01 – 77.38 
S4 n 3 3 3 
Mean ± SD 74.07 ± 6.92 79.00 ± 6.82 65.89 ± 11.96 
Range (min-max) 66.50 – 80.07 71.37 – 84.50 52.09 – 73.19 
S5 n 3 3 3 
Mean ± SD 76.82 ± 5.28 72.76 ± 10.81 59.47 ± 6.40 
Range (min-max) 72.87 – 82.79 64.35 – 84.95 53.08 – 65.89 
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Figure 7. Column graph illustrating the mean percentage transfer of FLC across each 
segment of Q1 following 60 mins. 
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Figure 8. Column graph illustrating the mean percentage transfer of CHL across each 
segment of Q1 following 60 min. 
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Figure 9. Column graph illustrating the mean percentage transfer of DIG across each 
segment of Q1 following 60 min. 
Statistical analysis determined that there were no significant differences between the transfer 
of FLC, CHL and DIG across the length of Q1 alone (P = 0.34, P = 0.23 and P = 0.60, 
respectively).  
 
3.3.3 Experiment 2: Comparison of proportion of glucose transferred with respect to 
tissue duration in storage 
Summary statistics of transfer of glucose across the wall of rat gut sacs from Q1 incubated for 
60 minutes following 0.5 hours storage at 4 ºC and gut sacs incubated following 24 hours 
storage at 4 ºC are shown in Table 21. 
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Analysis using two tailed t-tests demonstrated that there was a significant difference between 
the mean transfer of these two groups (P = 0.01). This is displayed in Figure 10. 
Table 21. Summary statistics of gut sacs incubated for 60 minutes following 0.5 hours cold 
storage vs those incubated for 60 minutes following 24 hours cold storage. n = number of gut 
sacs. 
 0.5 hour storage 24 hour storage 
n 18 14 
Glucose mean % transfer ± SD 89.70 ± 1.74 95.39 ± 0.85 
Range 75.44 – 97.52 88.21 – 99.53 
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Figure 10. Column graph illustrating the mean ± SE of transfer of glucose into gut sacs 
stored at 4ºC for 0.5 vs 24 hours. 
 
3.3.4 Experiment 3: Investigation into effect of aeration of tissue medium on glucose 
transfer 
Summary statistics of transfer of glucose across the wall of Q1 gut sacs incubated for 60 
minutes with and without the presence of Carbonox (95% oxygen, 5 % carbon dioxide) are 
shown in Table 22. 
Analysis using two tailed t-tests demonstrated that there was an extremely significant 
difference between the mean proportions of glucose transferred in these two groups (P < 
0.001). This is displayed in Figure 11. 
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Table 22. Summary statistics of gut sacs incubated without the presence of Carbonox vs those 
incubated with the presence of Carbonox following 60 mins. n= number of gut sacs. 
 Incubation without 
Carbonox  
Incubation with 
Carbonox 
n  12 12 
Glucose mean % 
transfer ± SD 
40.43 ± 2.67 65.50 ± 2.96 
Range 24.40 – 60.44 47.07 – 83.22 
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Figure 11. Column graph illustrating the mean ± SE of transfer of glucose into gut sacs 
incubated for 60 minutes with and without the presence of Carbonox.  
 
3.3.5 Experiment 4: Comparison of proportion of transfer of three drugs across the 
small intestine 
Summary statistics describing the mean transfer of each of the three drugs at intervals 
throughout the 60 minutes incubation time is shown in Table 23. This data is displayed as a 
linear graph in Figure 12, and a semi-log graph in Figure 13. All slopes were compared from 
time 0, where internal concentration was assumed to be 0, however this was unable to be 
depicted on semi-log graphs. 
No measurements of FLC could be achieved at 5 minutes as the concentration of FLC was 
below the lowest limit of quantification. 
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Table 23. Summary statistics of mean proportion of drug transferred throughout 60 minutes 
incubation. 
Minutes FLC mean % 
transfer ± SD  
(number of gut sacs) 
CHL mean % 
transfer ± SD 
(number of gut sacs) 
DIG mean % 
transfer ± SD  
(number of gut sacs) 
5 - (-) 10.17 ± 3.52 (15) 6.09 ± 2.56 (15) 
10 20.10 ± 8.59 (13) 9.80 ± 3.93 (22) 7.42 ± 2.16 (22) 
15 29.25 ± 11.25 (14) 23.14 ± 2.80 (16) 12.55 ± 2.69 (16) 
20 28.53 ± 6.79 (16) 31.77 ± 7.89 (16) 21.59 ± 3.67 (16) 
30 41.54 ± 10.59 (9) 39.06 ± 12.02 (15) 27.89 ± 10.21 (15) 
45 61.79 ± 12.17 (15) 50.28 ± 8.20 (17) 46.76 ± 11.72 (17) 
60 78.77 ± 6.76 (16) 77.22 ± 7.46 (17) 63.96 ± 9.32 (17) 
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Figure 12. Linear graph of transfer of drugs across 60 minutes of incubation. 
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Figure 13. Semi log (Y axis) graph of transfer of drugs across 60 minutes of incubation.   
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From Figure 13 it appears that the slopes of all three drugs appear to ‘level out’ from 20 
minutes of incubation. Figure 14 displays the slopes of the drugs throughout the first 20 
minutes of incubation only. 
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Figure 14. Semi log (Y axis) of comparative proportion of drug transferred across first 20 
minutes of incubation.   
An unbalanced design ANOVA was used to investigate whether there were any significant 
differences between the transfer of each of the three drugs at 5, 10, 15 and 20 minutes 
incubation. The data was then back-transformed to better fit the assumption. The back-
transformed transfer means at each time point are shown in Figure 15. 
 
 
Figure 15.  Linear graph describing back-transformed transfer means and standard errors of 
each drug from 5 to 20 minutes of incubation. 
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Analysis determined there was a significant interaction between drug and time (P < 0.001). 
The results of the analysis of significance between each drug are described in Table 24. 
Table 24. Statistical significance of comparative transfer of each of the three drugs at 5, 10, 
15 and 20 minutes of incubation. 
 5 minutes 10 minutes 15 minutes 20 minutes 
FLC vs CHL - Significant Non-significant Non-significant 
FLC vs DIG - Significant Significant Significant 
CHL vs DIG Significant Non-significant Significant Significant 
 
 
The transfer rate of each drug from 0 to 20 minutes of incubation is described in Table 25. 
Since a measurement was not able to be obtained from FLC at 5 minutes, the initial transfer 
of FLC was measured from 0 to 10 minutes.  
Table 25. Transfer rates of each drug from 0 to 20 minutes. Transfer rate was described as % 
transfer/minute. 
 0 to 5 minutes 5 to 10 (0 to 10 
for FLC) minutes 
10 to 15 minutes 15 to 20 minutes 
FLC - 1.82 1.79 0.13 
CHL 1.93 -0.16 2.83 1.56 
DIG 1.12 0.31 1.03 1.81 
 
FLZ flux was significantly different to DIG at all time points, however only significantly 
different between CHL at 0 to 10 minutes.  
There was a significant difference between CHL and DIG transfer at all time points except at 
10 minutes.  
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3.3.6 Experiment 5: Effect of a P-gp inhibitor on proportion of transfer of each drug 
Summary statistics describing the mean ± SD transfer of each drug with the addition of two 
different concentrations of verapamil, at intervals throughout the 60 minutes incubation time 
is shown in Table 26. This data is displayed in Figure 16. 
No measurements of FLC could be achieved at 5 minutes as the concentration of FLC was 
below the lowest limit of quantification. 
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Table 26. Summary statistics of mean ± SD transfer of three drugs with the inclusion of verapamil throughout 5 to 20 minutes incubation 
 5 µg/mL verapamil 25 µg/mL verapamil 
Minutes FLC mean % 
transfer ± SD 
(number of gut 
sacs) 
CHL mean % 
transfer ± SD 
(number of gut 
sacs) 
DIG mean % 
transfer ± SD 
(number of gut 
sacs) 
FLC mean % 
transfer ± SD 
(number of gut 
sacs) 
CHL mean % 
transfer ± SD 
(number of gut 
sacs) 
DIG mean % 
transfer ± SD 
(number of gut 
sacs) 
5 - (0) 9.31 ± 3.10 (12) 7.86 ± 2.49 (12) - (0) 9.80 ± 3.08 (12) 6.84 ± 2.64 (12) 
10 8.10 ± 5.69 (12) 18.05 ± 3.10 (12) 13.69 ± 1.76 (12) 16.08 ± 3.81 (12) 13.51 ± 1.77 (12) 11.84 ± 1.65 (12) 
15 15.43 ± 7.02 (12) 21.63 ± 2.36 (12) 16.31 ± 1.79 (12) 19.97 ± 7.77 (10) 20.27 ± 3.42 (10) 15.11 ± 2.11 (10) 
20 33.62 ± 2.00(12) 31.54 ± 2.51 (12) 21.21 ± 3.51 (12) 23.29 ± 7.73 (11) 24.53 ± 1.95 (11) 17.57 ± 1.64 (11) 
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Figure 16. Semi log (Y axis) mean ± SD of comparative proportion of drug transferred 
throughout 5 to 20 minutes of incubation, with a) no verapamil, b) the addition of 5 µg/mL 
verapamil, and c) the addition of 25 µg/mL verapamil. 
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An unbalanced design ANOVA was used to investigate whether there were any significant 
differences between the transfer of each of the drugs at 5, 10, 15 and 20 minutes incubation 
with the addition of two concentrations of verapamil. The data was then back-transformed to 
better fit the assumption. The back-transformed transfer means at each time point are shown 
in Figure 17. 
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a)  
 
b)  
 
c)  
Figure 17. Column graphs illustrating the back-transformed means ± SE of proportion of 
drug transferred with a) no verapamil, b) the addition of 5 µg/mL verapamil, and c) the 
addition of 25 µg/mL verapamil. 
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Analysis determined there was a significant interaction between drug and time with the 
inclusion of 5 µg/mL verapamil (P < 0.001). However, no significant interaction was seen 
between drug and time with the inclusion of 25 µg/mL verapamil (P = 0.425). 
The results of the analysis of significance between each drug with the inclusion of 5 µg/mL 
and 25 µg/mL verapamil are described in Tables 27 and 28, respectively. 
Table 27. Statistical significance of comparative transfer of each of the three drugs at 5, 10, 
15 and 20 minutes of incubation, with the addition of 5 µg/mL verapamil. 
 5 minutes 10 minutes 15 minutes 20 minutes 
FLC vs CHL - Significant Significant Non-significant 
FLC vs DIG - Significant Non-significant Significant 
CHL vs DIG Non-significant Non-significant Significant Significant 
 
Table 28. Statistical significance of comparative transfer of each of the three drugs at 5, 10, 
15 and 20 minutes of incubation, with the addition of 25 µg/mL verapamil. 
 5 minutes 10 minutes 15 minutes 20 minutes 
FLC vs CHL - Non-significant Non-significant Non-significant 
FLC vs DIG - Significant Non-significant Significant 
CHL vs DIG Significant Non-significant Significant Significant 
 
The transfer rate of each of the drugs with the inclusion of 5 µg/mL and 25 µg/mL from 0 to 
20 minutes of incubation are described in Tables 29 and 30, respectively. Since a 
measurement was not able to be obtained from FLC at 5 minutes, the initial transfer of FLC 
was measured from 0 to 10 minutes.  
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Table 29. Transfer rates of each drug from 0 to 20 minutes with the addition of 5 µg/mL 
verapamil. Transfer rate was described as % transfer/minute. 
 0 to 5 minutes 5 to 10 (0 to 10 
for FLC) minutes 
10 to 15 minutes 15 to 20 minutes 
FLC - 0.62 1.48 3.99 
CHL 1.76 1.80 0.74 1.98 
DIG 1.49 1.23 0.52 0.95 
 
Table 30. Transfer rates of each drug from 0 to 20 minutes with the addition of 25 µg/mL 
verapamil. Transfer rate was described as % transfer/minute. 
 0 to 5 minutes 5 to 10 (0 to 10 
for FLC) minutes 
10 to 15 minutes 15 to 20 minutes 
FLC - 1.56 0.54 0.74 
CHL 1.87 0.81 1.32 0.89 
DIG 1.28 1.07 0.65 0.50 
 
An unbalanced design ANOVA was also used to investigate whether there were any 
significant differences in transfer within each of the drugs with the addition of two 
concentrations of verapamil. The data was then back-transformed to better fit the assumption.  
Analysis determined there was a significant interaction between verapamil concentration and 
time in all three target drugs (P < 0.001). 
The back-transformed transfer means of FLC at each time point are shown in Figure 18. 
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Figure 18. Column graph illustrating the back-transformed transfer means and standard 
errors of proportion of FLC transferred with three different concentrations of verapamil. 
 
The results describing the analysis of significance of FLC transfer with the inclusion of 
different concentrations of verapamil is described in Table 31. As previously discussed, no 
measurements of FLC were obtained at 5 minutes. 
Table 31. Statistical significance of proportion of FLC transferred with three verapamil 
concentrations at 5, 10, 15 and 20 minutes of incubation. 
 5 minutes 10 minutes 15 minutes 20 minutes 
0 vs 5 µg/mL - Significant Significant Non-significant 
0 vs 25 µg/mL - Non-significant Significant Non-significant 
5 vs 25 µg/mL - Significant Non-significant Significant 
 
The transfer rate of FLC with the inclusion of 0, 5 and 25 µg/mL verapamil from 0 to 20 
minutes of incubation are described in Table 32. Since a measurement was not able to be 
obtained from FLC at 5 minutes, the initial transfer with each concentration of verapamil was 
measured from 0 to 10 minutes.  
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Table 32. Transfer rates of FLC from 0 to 20 minutes with the addition of verapamil. 
Transfer rate was described as % transfer/minute. 
 0 to 5 minutes 5 to 10 minutes 10 to 15 minutes 15 to 20 minutes 
0 µg/mL - 1.82 1.79 0.13 
5 µg/mL - 0.62 1.48 3.99 
25 µg/mL - 1.56 0.54 0.74 
 
The back-transformed transfer means of CHL at each time point are shown in Figure 19. 
 
Figure 19. Column graph illustrating the back-transformed transfer means and standard 
errors of proportion of CHL transferred with three different concentrations of verapamil. 
 
The results describing the analysis of significance of CHL transfer with the inclusion of 
different concentrations of verapamil is described in Table 33. 
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Table 33. Statistical significance of proportion of CHL transferred with each of the three 
verapamil concentrations at 5, 10, 15 and 20 minutes of incubation. 
 5 minutes 10 minutes 15 minutes 20 minutes 
0 vs 5 µg/mL Non-significant Significant Non-significant Non-significant 
0 vs 25 µg/mL Non-significant Significant Non-significant Significant 
5 vs 25 µg/mL Non-significant Significant Non-significant Significant 
 
The transfer rates of CHL with the inclusion of 0, 5 and 25 µg/mL from 0 to 20 minutes of 
incubation are described in Table 34. 
 
Table 34. Transfer rates of CHL from 0 to 20 minutes with the addition of verapamil. 
Transfer rate was described as % transfer/minute. 
 0 to 5 minutes 5 to 10 minutes  10 to 15 minutes 15 to 20 minutes 
0 µg/mL 1.93 -0.16 2.83 1.56 
5 µg/mL 1.76 1.92 0.74 1.98 
25 µg/mL 1.87 0.81 1.32 0.89 
 
 
 
 
 
 
 
 
 
 
67 
 
The back-transformed transfer means of DIG at each time point are shown in Figure 20. 
 
Figure 20. Column graph illustrating the back-transformed transfer means and standard 
errors of proportion of DIG transferred with three different concentrations of verapamil. 
 
The results describing the analysis of significance in DIG transfer with the inclusion of 
different concentrations of verapamil is described in Table 35. 
Table 35. Statistical significance of proportion of DIG transferred with each of the three 
verapamil concentrations at 5, 10, 15 and 20 minutes of incubation. 
 5 minutes 10 minutes 15 minutes 20 minutes 
0 vs 5 µg/mL Significant Significant Significant Non-significant 
0 vs 25 µg/mL Non-significant Significant Non-significant Non-significant 
5 vs 25 µg/mL Non-significant Non-significant Non-significant Non-significant 
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The transfer rates of DIG with the inclusion of 0, 5 and 25 µg/mL from 0 to 20 minutes of 
incubation are described in Table 36.  
Table 36. Transfer rates of DIG from 0 to 20 minutes with the addition of verapamil. 
Transfer rate was described as % transfer/minute. 
 0 to 5 minutes 5 to 10 minutes 10 to 15  minutes 15 to 20 minutes 
0 µg/mL 1.12 0.31 1.03 1.81 
5 µg/mL 1.49 1.23 0.52 0.95 
25 µg/mL 1.28 1.07 0.65 0.50 
 
The transfer of FLC was significantly different with the addition of 5 µg/mL verapamil, 
versus no verapamil, at 0 to 15 minutes incubation. This difference was not noted with the 
addition of 25 µg/mL verapamil. 
The transfer of CHL with the addition of verapamil at both concentrations of verapamil were 
significantly different versus no verapamil at 10 minutes incubation. The addition of 25 
µg/mL significantly differed to the addition of no verapamil at 20 minutes incubation. 
The transfer of DIG was significantly different with the addition of 5 µg/mL verapamil, 
versus no verapamil, at 0 to 15 minutes incubation. This difference, however, was not noted 
with the addition of 25 µg/mL verapamil. 
 
 
3.3.7 Experiment 6: Proportion of glucose transferred across possum small intestine 
Summary statistics describing the transfer of glucose into possum gut sacs are shown in Table 
37. 
Due to the differences between each individual possum, and small sample size, no further 
statistical analysis was performed. 
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Table 37. Summary statistics describing glucose transfer across the gut wall of each 
individual possum, grouped by incubation period. 
Incubation period (minutes) Possum 
ID no. 
n = number of 
sacs from Q1 
Mean ± SD 
30 5 8 73.55 ± 2.29 
6 9 78.86 ± 1.58 
10 9 79.95 ± 3.24 
Total 30 minute average  26 77.61 ± 3.67 
60 1 7 49.39 ± 4.38 
2 8 67.33 ± 1.78 
7 8 88.84 ± 2.54 
Total 60 minute average  23 70.26 ± 16.34 
90 3 10 76.23 ± 1.38 
4 9 91.13 ± 1.92 
8 10 85.85 ± 2.56 
9 10 91.28 ± 2.85 
Total 90 minute average  39 86.00 ± 6.59 
  
The average transfer following 30 minutes incubation was 77.61 %, with standard deviation 
of 3.67 %. The average transfer following 60 minutes incubation was lower, at 70.26 %, and 
in addition demonstrated a large standard deviation, of 16.34 %. The average transfer 
following 90 minutes incubation was 86.00 %, with standard deviation of 6.59 %. 
 
3.3.8 Experiment 7: Lactate dehydrogenase stability 
Summary statistics of LDH levels obtained from incubation with rat gut sacs at various time 
points are shown in Table 38. Summary statistics of LDH levels obtained from incubation 
with possum gut sacs at various time points are shown in Table 39. 
Due to inconsistent results, no further statistical analysis was done on either data set. 
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Table 38. Summary statistics of LDH levels found externally and internally to rat gut sacs 
incubated for various times. Internal LDH concentrations described are from segments 1, 3 
and 5 respectively. 
Incubation 
period 
(minutes) 
External LDH 
concentration (U/L) 
Internal LDH 
concentration (U/L) 
Mean internal LDH 
concentration (U/L) 
± SD 
5 8.29 5732.02 
3633.26 
3919.58 
4428.29 ± 1138.11 
10 4.988 3366.03 
4145.09 
3429.44 
3646.75 ± 432.72 
15 7.997 2893.45 
2184.45 
2381.38 
2486.42 ± 365.99 
20 9.946 2171.24 
1989.22 
2403.07 
2187.84 ± 207.42 
30 9.069 167.27 
158.09 
79.79 
135.05 ± 48.08 
45 657.785 5792.37 
4669.41 
4571.99 
5011.25 ± 678.22 
60 6.134 98.01 
52.71 
56.11 
68.95 ± 25.23 
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Table 39. Summary statistics of LDH levels found externally and internally to possum gut 
sacs incubated for various times.  
Incubation 
period 
(minutes) 
Possum 
ID no. 
External LDH 
concentration 
(U/L) 
Mean internal 
LDH 
concentration 
(U/L) ± SD 
Internal LDH 
concentration 
range (min-max) 
30 
 
5 27.79 525.34 ± 124.54 435.01 – 789.58 
6 87.15 1671.82 ± 810.51 858.50 – 2910.47 
10 133.64 887.45 ± 259.75 688.02 – 1461.57 
Total 30 
minute average 
  1047.55 ± 687.70  
60 
 
2 331.37 1424.50 ± 295.99 911.72 – 1875.60 
7 203.89 1158.27 ± 575.41 431.97 – 2001.50 
Total 60 
minute average 
  1291.39 ± 462.92  
90 
 
3 169.90 835.44 ± 457.46 409.55 – 1765.10 
4 5.98 6.63 ± 6.85 0.73 – 17.91 
8 317.32 1648.42 ± 390.74 1098.30 – 1974.51 
9 203.02 1555.16 ± 610.06 1079.09 – 2241.26 
Total 90 
minute average 
  1123.06 ± 747.19  
 
 
 
 
 
 
 
 
72 
 
4 Discussion 
 
The most interesting observations from this study were: 
1. Gut sacs taken from the proximal quarter of the small intestine show significantly 
greater drug transfer than the distal three quarters. 
2. High consistency is observed in drug transfer within gut sacs from the same animal, 
however there are differences between individual animals. 
3. Optimum transfer of drug appears to occur from 0 to 20 minutes incubation. 
4. As expected, the transfer of DIG was significantly lower at 20 minutes and 60 
minutes of incubation compared to the serosal concentration of FLC and CHL. There 
was negligible difference in FLC and CHL transfer at both 20 and 60 minutes.  
5. The addition of verapamil, a P-gp inhibitor, at the concentration of 5 µg/mL increased 
the transfer of DIG across the gut wall initially, however the final concentrations of 
DIG following 20 minutes incubation without verapamil, and the addition of two 
concentrations of verapamil were not significantly different. 
6. Following 20 minutes incubation, the addition of 25 µg/mL verapamil resulted in 
significantly lower serosal concentrations of both FLC and CHL. There was no 
significant difference between the serosal concentrations of both drugs with the 
addition of 5 µg/mL verapamil when compared to no verapamil. 
7. Storage of the tissue at 4 ºC for 24 hours showed a significant difference in glucose 
transfer from that stored for only 0.5 hours. 
8. The addition of aeration to the medium was highly significant in increasing glucose 
transfer across the gut wall. 
9. EGSM has significant limitations to assess drug transfer across gut tissue in those 
animals that are not held in close proximity to the apparatus required for the model. 
10. Measurements of LDH to assess tissue viability were problematic and other indicators 
of cell toxicity should be explored. 
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4.1 Development and validation of drug assays by HPLC 
The HPLC method developed and validated was found to be reliable and repeatable 
(precision range 1.42 to 4.00 %) in detecting all four target drugs, including florfenicol (IS). 
The LLOQ of all drugs, particularly FLC (at 2.5 µg/mL), were higher than other LLOQs 
reported in the literature (for example:  0.1 µg/mL LLOQ of FLC was previously reported 
[Black et al., 2014], 3 ng/mL LLOQ of CHL [Iqbal et al., 2006], and 25 ng/mL LLOQ of 
DIG [Varma et al., 2004]), however such sensitivity was sacrificed in order to optimise the 
detection of all four drugs at the same time. Being an in-vitro model, there was flexibility in 
modifying the drug concentrations in the external medium so that the LLOQ was 
inconsequential (except for the unforeseen low concentrations of FLC that occurred in the 
serosal fluid prior to 10 minutes of incubation). However it is a perceived strength of this 
investigation that the transfer of FLC, CHL and DIG across the same tissue could be 
quantified simultaneously, and provides a meaningful comparison of transfer between the 
target substrates under the same conditions.  
One of the major issues encountered during drug assay development was the instability of 
some of the target drugs. When stored at 4º C, FLC was found to degrade significantly after 
seven days. The CHL peak did not degrade significantly in chromatogram peak area when 
repeat measurements of the same sample were undertaken over 14 days, however if the 
working solution was stored for longer than 10 days it generated a new metabolite that 
created a new peak on the chromatogram (chromatogram not shown). Whilst this peak was 
insignificant in size, it interfered with that of FLC, and so needed to be avoided. To prevent 
this issue, new working solutions were made at the beginning of each week, and used for a 
maximum of five days. Following incubation, samples were assayed within 48 hours, except 
for those samples collected after 10 and 15 minutes incubation in Experiment 4 (rat EGSM), 
due to a problem with the HPLC machine. In this case, the samples were not quantified for 
six days. No additional peaks were noted in these assays, and based on the stability testing 
prior to experimentation, it is not anticipated that there would have been a significant change 
in chromatogram peak area during this time. 
Whilst this method does not consider any drug concentrations possibly bound to proteins, 
previous studies using the EGSM have also not quantified this concentration. Time 
restrictions limited our ability to create a method to measure such concentrations. 
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4.2 Studies into drug flux across the intestine 
4.2.1 Experiment 1: Drug transfer along the length of the small intestine 
Experiment 1 determined that the transfer of the target drugs differed along the length of the 
small intestine of the rat. The transfer of FLC was significantly greater in all rats in Q1 than 
in Q2, 3 and 4, and the transfer of CHL and DIG were significantly higher in Q1 in Rat 2 and 
Rat 3, with no significant differences seen between the quarters in Rat 1. Due to the small 
sample size, rat was a significant factor in determining transfer proportions, however the 
strong correlation seen between Rat 2 and Rat 3 suggest that this factor might become 
negligible with a larger sample size. Whilst the rats used for experimentation were from a 
homogenous group, there were small differences in age (ranging from eight to thirteen weeks 
of age) that may have contributed to differences observed between Rat 1 versus Rat 2 and Rat 
3.  
These results were therefore taken to suggest that Q1 would demonstrate the greatest transfer, 
and this quadrant was used exclusively throughout the remaining experimentation. 
Experiment 1a then determined that there was no significant differences in transfer along the 
length of Q1, allowing for all five segments to be grouped together for statistical analysis.  
Although previous studies have used individual sections of the intestine (ie. Only jejunum, or 
only ileum), they did not specify how each intestinal section was differentiated. This study 
assumed that dividing the length of the small intestine into quarters should result in consistent 
tissue architecture within each quarter of each animal, regardless of the animal’s size.  
There are differences in intestinal structure, as the duodenum and jejunum are slightly wider 
than the ileum, resulting in a larger surface area, however these sections are also thicker 
(Mahadevan, 2014). There are also an increased number of mucosal folds found on the 
surface of the proximal jejunum, however these decrease gradually in number along the 
length of the intestinal wall (Young et al., 2013). Neither of these structural differences 
between sections of the small intestine are likely to alone account for the significant 
difference in transfer seen between Q1 and Q2. The significant differences seen between Q1 
and the remaining quarters can therefore be suggested as evidence to support the validity of 
the functioning small intestinal tissue. 
Consequently there may be a number of factors that could influence the location at which 
drugs and nutrients may be most effectively absorbed in the small intestine, including age of 
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the animal, and differences between individual drugs in respect to chemical structure and 
size. It is therefore suggested that the observations reported here may be drug and subject 
specific. Repetition of Experiment 1 may be necessary when investigating different drugs, 
different species, or different ages of rats to ensure that the most effective part of the small 
intestine is being used for experimentation, or that the segment of small intestinal wall area 
being used for the model, is consistent. 
 
4.2.2 Experiments 2 (Comparison of proportion of drug transfer with respect to tissue 
duration in cold storage) and 3 (Investigation into effect of aeration of tissue medium on 
transfer): Glucose transfer across the small intestine in the rat 
The extent of glucose transfer demonstrated in both Experiments 2 (0.5 vs 24 hour storage) 
and 3 (± tissue aeration) appear to contradict the transfer patterns demonstrated in previous 
EGSM studies (Nagler et al., 1960, Barthe et al., 1998b). Both Barthe et al. (1998b) and 
Nagler et al. (1960) demonstrated higher concentrations of glucose in the serosal fluid of gut 
sacs (fluid inside sac) compared to the mucosal fluid (fluid outside sac), against the 
concentration gradient (366% following 75 minutes incubation and 177% following 60 
minutes incubation of the mucosal concentration, respectively). This was taken as evidence to 
prove active transport. Whilst the serosal glucose concentrations in Experiments 2 (0.5 vs 24 
hour storage) and 3 (± tissue aeration) did reach equilibrated concentrations to those of the 
mucosal concentrations throughout the 60 minutes incubation, they did not reach the 
concentrations described in these previous papers, and in turn this experiment does not 
definitively prove that the gut sacs in this study are viable. However, Nagler et al. (1960) 
suggested that approximately half of the glucose transported from the mucosal fluid was 
converted to lactic acid in the serosal fluid, which they also measured. In this study, no 
measurements of lactic acid were undertaken, which may have led to a lower than expected 
serosal glucose concentration in this study. Despite this, Barthe et al. (1998b) still 
demonstrated a significantly higher serosal concentration than both that found by Nagler et al. 
(1960) and what was found in this study. Reasons for this variation are unknown, and suggest 
the accuracy of this test may not be reliable without further repetition and a more accurate 
baseline. 
Paracellular transport refers to the transport of substances across an epithelium by passing 
through the space between cells (Flynn, 2008). It differs from active transport as it is not 
76 
 
influenced by tissue viability. Whilst paracellular transport was previously thought to be 
largely responsible for glucose transfer into the body, other studies have shown active 
transport more likely to be responsible in live animals (Uhing and Kimura, 1995a, Uhing and 
Kimura, 1995b). However its role in in-vitro models is not clearly defined, having only been 
quantified by Barthe et al. (1998b). Barthe et al. (1998b) did not find paracellular transport to 
be a significant factor in determining the transfer of glucose into gut sacs, however further 
research into its role is necessary in justifying the significant differences seen in glucose 
transfer between papers.  
Results from Experiment 3 (± tissue aeration) showed a significant difference in glucose 
transfer, with those aerated gut sacs displaying a significantly higher serosal concentration of 
glucose (65.50 ± 2.96 % transfer with aeration vs 40.43 ± 2.67 % transfer without aeration). 
These results support the hypothesis that the presence of oxygen (95%) : carbon dioxide (5%) 
in the tissue medium increases tissue viability by mimicking bodily conditions. This is also 
evidence to support the gut sacs demonstrating some activity especially when incubated in an 
aerated environment, despite the lower than anticipated glucose transfer.  
Results from Experiment 2 (0.5 vs 24 hour storage), contradicted the hypothesis that the 
tissue stored for 24 hours may remain viable, and therefore display similar glucose transfer, 
with the 24 hour stored tissue displaying significantly higher glucose transfer (89.70 ± 1.74 % 
transfer with 0.5 hour storage vs 95.39 ± 0.85 % transfer with 24 hour storage) (P = 0.01). 
However, the viability of this tissue is supported by the results observed in Experiment 3 (± 
tissue aeration), where the glucose transfer observed in the non-aerated, and expectedly non-
viable, gut sacs was highly significantly lower, at only 40.43 ± 2.67 %. This result suggests 
that non-viable gut sacs would result in significantly lower glucose transfer, and the results 
observed in Experiment 2 (0.5 vs 24 hour storage) may support viable tissue during 60 
minutes of incubation, despite the statistically significant difference. 
The serosal glucose concentration following 60 minutes incubation found in the aerated gut 
sacs of Experiment 3 (65.50 ± 2.96 %) was significantly lower than those gut sacs stored for 
0.5 hours in Experiment 2 (89.70 ± 1.74 %). It was anticipated that they would be 
comparable, as tissue in both experiments was only stored for the regular short time prior to 
experimentation, so the reason for this is unknown, but unfortunately is most likely due to the 
small sample size, and differences between individual rats. 
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The influence of using rats from a non-related study must also be considered. The assumption 
was made that the previous unrelated surgery had no influence on the GIT of the studied rats, 
however this assumption was not proven. It is possible that the previous anaesthesias and 
surgeries may have influenced intestinal validity. 
A number of drugs were investigated over many months of this study to find a negative 
control; that is a drug that had negligible or low transfer across the intestinal wall. Such drugs 
included phenol red (Alam et al., 2011), vancomycin (Hossion, 2014) and gentamicin 
(Hossion, 2014) however none were suitable for use in the HPLC method described due to 
interference and overlapping peaks, and no other suitable methods of detection were 
available. Due to a lack of success with a negative control, this aspect was abandoned. 
 
4.3 Transfer curves of target drugs with and without verapamil 
4.3.1 Experiment 4: Comparison of proportion of drug transfer across small intestine 
All drugs had an initial concentration of 25 µg/mL in the external medium as it was expected 
that this concentration would be detectable with the use of the described chromatogram, 
whilst not being so large as to saturate the solution and impair drug transfer, which has been 
of concern in previous studies (Boüer et al., 1999). This concentration is within the range of 
drug concentrations previously applied to the EGSM. 
The observed curves of all three drugs appear to flatten out (semi log graph [y axis in log] 
scale; Figure 13) following the observation at approximately 20 minutes incubation. This is 
consistent with the hyperbolic curve of transfer observed by Barthe et al. (1998a) over 90 
minutes of incubation. This reduction in transfer rate may be due to saturation of the serosal 
medium, and the equivocating concentrations internally and externally to the gut sacs, 
although the results described by Barthe et al. (1998b) regarding significantly higher serosal 
glucose concentration compared to mucosal concentration, as described in Section 4.2.2, 
would suggest that this would not be the case in fully functioning tissue. This decrease in 
transfer rate may also be due to a decrease in cellular activity due to decreasing tissue 
viability throughout the incubation process, signifying that the incubation conditions are not 
optimal for cell viability. Contrarily, this decrease in transfer rate may also be explained as 
occurring due to an increase in tissue viability. Whilst the gut sacs were incubated in the 
heated medium for 10 minutes prior to experimentation, it is not known if this time period 
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was long enough to bring the tissue back to body temperature, and maximise viability. Should 
the tissue be increasing in viability during experimentation, increased activity by efflux 
transporter proteins may act to reduce the amount of drug reaching the serosal medium. 
However, as Barthe et al. (1998b) did not reduce the temperature of their tissue, and still 
observed a reduction in transfer rate following 20 minutes of incubation, this explanation is 
less likely. Consideration of these aspects indicates that the model is probably also sensitive 
to the drug concentration initially applied as well as the time required for the tissue to re-
equilibrate to physiological temperature. Thus further attention is required to optimise these 
variables.  
The transfer of DIG fulfilled the hypothesis that anticipated the demonstration of slower and 
reduced transfer than FLC and CHL due to being a P-gp substrate (Cavet et al., 1996) as 
illustrated in Figure 15, assuming that P-gp has efflux properties. DIG was found to be 
significantly lower (P < 0.001) at 10, 15 and 20 minutes compared to FLC, and at 5, 15 and 
20 minutes compared to CHL. Whilst this did fulfil the described hypothesis, the effect of 
paracellular transport on the transfer of DIG is unquantified. Since DIG has a significantly 
higher molecular weight (780 g/mol) than both FLC (306 g/mol) and CHL (323 g/mol), 
significant paracellular transport would also result in significantly higher serosal FLC and 
CHL concentrations. The difference in transfer between FLC and CHL at both 20 minutes 
(approximately 29% and 32%, respectively) and 60 minutes (approximately 79% and 77%, 
respectively) was negligible.  In contrast DIG had an approximate concentration of 22% at 20 
minutes and 64% at 60 minutes.  
There were no significant differences observed between FLC and CHL transfer, except at 10 
minutes, where FLC showed a significantly higher serosal concentration than CHL (20.10 ± 
8.59 % transfer compared to 9.80 ± 3.93 % transfer, respectively) (P < 0.001). This time point 
was also the only point where CHL was not significantly higher than DIG. Data gained from 
CHL transfer showed a decrease in serosal concentration from 5 to 10 minutes, so the data at 
10 minutes may be an outlier due to the small sample size.  
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4.3.2 Experiment 5: Effect of a P-gp inhibitor on proportion of transfer of the three 
drugs 
With the addition of verapamil, a recognised P-gp inhibitor (Cavet et al., 1996), it was 
hypothesised that the serosal concentration of DIG would increase. Verapamil was chosen as 
a suitable inhibitor as it did not appear to interfere with any of the target drug peaks observed 
on the chromatogram. The addition of 5 µg/mL verapamil resulted in significantly higher 
serosal concentrations of DIG at 5, 10 and 15 minutes, although the same results were not 
observed with the addition of 25 µg/mL verapamil (illustrated in Figure 20). Despite the 
initial increased transfer observed with the addition of 5 µg/mL verapamil, at the end of the 
20 minute incubation period there were no significant differences between the final serosal 
DIG concentration observed without verapamil, and with either of the addition of the two 
investigated concentrations. These results are contradictory to Barthe et al.’s (1998b) 
observations, where following 90 minutes incubation with 45 µg/mL verapamil, a 2.5-fold 
increase in serosal digoxin was noted. This increased rate of transfer was seen throughout the 
90 minutes of incubation, and so this increased serosal DIG was not due only by the extended 
incubation period. 
Significant changes in the serosal concentration of FLC and CHL with the addition of either 
concentration of verapamil were not anticipated.  
However, FLC absorption with the addition of verapamil appeared unpredictable. With the 
addition of 5 µg/mL, measurements at 10 minutes showed to be significantly lower than the 
other two observations, however then displayed a high rate of transfer to end at 20 minutes 
incubation with a serosal concentration significantly higher than that with the addition of 25 
µg/mL. However the addition of 25 µg/mL resulted in an initial high transfer rate to 10 
minutes incubation, which then greatly decreased, to end at 20 minutes incubation with the 
lowest serosal FLC concentration. 
CHL appeared to confirm the hypothesis of no change, as the addition of either 
concentrations of verapamil did not appear to increase the overall absorption. Whilst the 
measurement at 10 minutes without the addition of verapamil was significantly lower than 
with the addition of both concentrations of verapamil, this was the observation previously 
noted as being unexpected, as it was lower than the measurement at five minutes. The other 
unexpected result is the measurement observed at 20 minutes incubation with the addition of 
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25 µg/mL verapamil, which was significantly lower than the other two observations at 20 
minutes. 
Due to the significant increases seen with the addition of 45 µg/mL verapamil by Barthe et al. 
(1998b), it was anticipated that the larger concentration of 25 µg/mL verapamil would result 
in a significant increase in the serosal DIG concentration. However, this was not observed, 
with no differences seen between the final 20 minute serosal DIG concentrations, and the 
final serosal concentrations of FLC and CHL with the addition of 25 µg/mL verapamil 
measuring significantly lower than concentrations with 5 µg/mL verapamil, and no 
verapamil. These results are completely unexpected, and suggest the dosage rates used in this 
study may not appropriate for use in this model or there may have been some interaction 
between the verapamil and one or more of the drugs that affected transfer of FLC and CHL. 
No pattern was seen between the transfer rates of the drugs in the initial observations. 
Similarly, no distinct patterns were observed between the target drugs with the addition of 
verapamil, despite all observations being within a similar range. The large variability in the 
transfer rates of FLC with and without the presence of verapamil demonstrates the risk of 
calculating such rates when dealing with a small number of observations. However, DIG with 
the addition of both concentrations of verapamil resulted in initially higher transfer rates that 
quickly dropped off, compared to the increasing transfer rates observed when no verapamil 
was present. Whilst the final concentrations of DIG observed were not significantly different, 
the addition of verapamil may have increased the rate at which DIG was transferred across 
the gut wall. However it must be noted that the increasing transfer seen in DIG without the 
presence of verapamil is inconsistent with the typical hyperbolic transfer curve, and may not 
be reflective of results demonstrated in a larger sample size.  
Verapamil was chosen due to it not interfering with any of the peaks in the chromatographic 
method described. Should another chromatographic method with different target drugs, or 
another method of drug detection be used, another P-gp inhibitor such as quinidine may also 
be tested and may result in more predictable results. 
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4.4 Experiment 6: Transfer in possum EGSM 
The possum EGSM was designed to assist in the optimisation of the model for use for those 
species that are not readily available in the laboratory. Unfortunately this study was greatly 
restricted due to an unexpected limitation of access to fresh tissue, resulting in a small sample 
size. It is also recognised that two different species of possums were incorporated into the 
experimentation. Initially it was decided that any results would be compared among the same 
species only. However as insufficient numbers of intestines were obtained over the 
experimental period (approximately 18 months), the decision was made to make some 
superficial groups and report the observations.  
This has resulted in unexpectedly grouped results, for example all possums investigated at 30 
minutes incubation were male, whilst all possums incubated at 90 minutes incubation were 
female. A greater sample size was anticipated to allow for further investigation into the 
effects age, species and sex may have on the rate of drug transfer. However, the current 
sample size does not allow for further statistical investigation. Additionally, many of the 
animals euthanased during this study showed signs of illness and malnutrition, the impact on 
tissue viability of which is unknown. Whilst it is not anticipated to have affected results, the 
differing methods of euthanasia between experimental rats and possums may influence 
results, limiting the ability to compare outcomes. 
Due to the expectantly small sample size, only the transfer of glucose was evaluated in the 
possum EGSM. At the three time points investigated (30, 60 and 90 minutes), no increasing 
pattern of glucose transfer with time was observed, contrary to the hypothesis. When the 
outlying data of possum one was removed, the mean ± SD of possums at 60 minutes 
incubation increased to 78.09 ± 11.31 percentage transfer, which was similar to that observed 
at 30 minutes incubation (77.61  ± 3.67 percentage transfer). Assuming the transfer of 
glucose in the possum would follow a similar curve to that seen in the rat, this may be due to 
the flattening out of the curve following the 30 minute mark and thus important time 
sampling points may have been omitted. Continuation of this study with a greater sample size 
would allow for investigation of glucose transfer at an increased number of time points, 
creating a more accurate curve without assumptions.  
Whilst the highest glucose transfer was seen at 90 minutes (86.00 ± 6.59 U/L), a lack of data 
quantifying cell toxicity, discussed below, does not allow for the assumption to be made that 
this is the optimal incubation period for possum small intestinal tissue. 
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The above EGSM using possum small intestine may also be restricted by the results from 
Experiment 2 (0.5 vs 24 hour storage), which did not definitively fulfil the anticipated 
hypothesis that tissue would remain viable following 24 hours storage. All tissue from this 
experiment was stored for 24 hours, and so is dependent on the conclusion and validation of 
Experiment 2. Further validation of the model using stored tissue in the rat will be necessary 
before this model can be optimised in additional species. 
 
4.5 Experiment 7: LDH testing 
The lactate dehydrogenase (LDH) concentrations did not reflect the expected results. Rather 
than increasing in the serosal (inside sac) fluid due to lessening tissue viability throughout the 
incubation process, serosal LDH levels during the incubation of rat intestines were seen to 
decrease over time, bar one outlier at 45 minutes. Based on this enzymes’ instability 
(discussed below), it is unknown whether this decrease could be attributed to the inhibition of 
LDH by the target drugs or medium, or its degradation to an untested metabolite. 
This decreasing pattern was not demonstrated in possum tissue, however the dramatic range 
seen in these results also makes it difficult to determine whether any patterns are being 
observed, or fulfil the aim of this experiment in helping to define the preferential incubation 
time for possum gut sacs. The removal of the two outliers within their experimental groups, 
possums four and six, does not result in better defined outcomes.  
Instructions from the manufacturer suggest running assays immediately following 
experimentation (Randox Laboratories Limited, 2010), however samples may be stored at 
room temperature (+20 to +25 ºC) for two to three days. Samples from possum three were 
assayed immediately following experimentation, and then again the following morning, with 
results decreasing from a mean of 835.44 ± 457.46 U/L to 72.85 ± 96.55 U/L, including one 
negative measurement. There are possible explanations for this, including room temperatures 
varying outside the recommended range, and samples in medium possibly being more 
unstable than those in serum, however this is strong evidence to suggest the instability of this 
enzyme, and apparent unsuitability for the use of LDH analysis in this type of 
experimentation. 
There is no published data in reference to expected LDH concentrations for viable and non-
viable tissue in the EGSM. Estimated concentrations expected in normal human serum vary 
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wildly within the first few days following birth, ranging from 290-775 U/L at 0-4 days of age, 
545-2000 U/L at 4-10 days of age, 180-430 U/L at 10 days-24 months, before finally settling 
at 100-210 U/L following 12 years of age (Randox Laboratories Limited, 2010). Similar 
variations may be identified in rats and possums with aging, however the limited sample size 
and lack of exact knowledge on the age of possums prevented making any such connections 
within our data. Given the apparent instability of LDH in the EGSM, histological and 
morphological testing (Barthe et al., 1998b), or the detection of alkaline phosphatase (ALP) 
(Barthe et al., 1998a) may be more accurate methods of quantifying tissue viability. 
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5 Conclusions and future directions 
As expected, the EGSM was more successful when using the tissues of a laboratory animal 
such as the rat. The model did demonstrate a difference in transfer of three target drugs across 
the rat intestine. It would be exciting to compare the transfer of the three target drugs across 
the intestinal wall of various species. However this study also demonstrated the difficulty in 
running the model with tissue from non-laboratory species. The University of Sydney has a 
colony of dunnarts (Sminthopsis murina) however the intestines of these small marsupials 
were considered too challenging to successfully evert and manipulate for the model.  
Despite the limitations of this study, the data provided above has demonstrated a number of 
relationships that have proved to support the validity of the EGSM using cold stored rat 
intestines. These results provided sufficient evidence to suggest that further research into the 
validity of the described EGSM is justified. 
Given the difference in results observed in glucose transfer between Experiments 2 (0.5 vs 24 
hour storage) and Experiment 3 (± tissue aeration) and other published data, it is suggested 
that a more accurate baseline of glucose transfer under standard conditions needs to be found, 
to allow for further research to continue. 
Whilst there was a significant difference measured between the glucose transfer observed in 
Experiment 2 (0.5 vs 24 hour storage), this does not appear to definitively disprove the 
validity of the cold stored tissue. It is expected that there will be a short window of 
opportunity during which the tissue will be viable, however investigations at an increased 
number of time points would determine the length of viability. This investigation will be 
greatly assisted by the determination of a more reliable method to quantify cell toxicity. 
Future studies would require a larger sample size, to hopefully minimise or eliminate the 
effect of the individual rat. Should this factor be eliminated, it would allow for the statistical 
analysis of all total gut sacs. Repetition would also assist in helping fit data to a potential 
model for the transfer of each drug, and assist in the identification of unusual or outlying 
data. The recommended number of rats to obtain statistical confidence is suggested to be 20 
to 30 based on the type of statistical analysis performed in this study (Associate Professor 
Peter Thomson, pers. comm.) 
This model, however, does not appear to be suitable for use with wildlife, as was initially 
hoped. As demonstrated in this study, access to fresh wildlife tissue is often unreliable and 
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inconsistent. Most wildlife will also be euthanased via pentobarbitone injection. The effect 
this has on tissue viability is unknown, and not quantified in this study. Additionally, tissue 
may also often be coming from sick or injured animals, which may also affect tissue viability. 
A lack of control over age and sex of animals gained for the study could possibly influence 
tissue viability, however investigations into differences in drug transfer in different ages and 
sexes of rats may be used as an indicator of whether this could influence transfer in additional 
species.  
The immediate future development of this study is to definitively validate the EGSM using 
cold stored small intestine in the rat. Whilst the future of the EGSM may not be based in 
wildlife research, the validation of use of cold stored tissue still has the potential to expand 
the use of this method to a number of new species. 
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Appendix 1 
 
Constituents of tissue medium TCC199: 
- This medium came as a powder 
- with Earle’s salts 
- No phenol red, L-glutamine nor sodium bicarbonate:  
- supplemented with 0.1 gm/L L-glutamine, 2.2 gm/L sodium bicarbonate 
-  9.09 gm power was reconstituted with  1 litre of water 
- Cell culture tested 
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